Methods for isolating and culturing human retinal progenitor cells

The method of isolating and culturing primary retinal cells from human samples addresses the challenge of retinal degeneration by enhancing cell viability and yield, generating non-immortal retinal progenitor cells that effectively treat retinal diseases and improve visual function.

JP7591828B2Active Publication Date: 2024-11-29RGT UNIV OF CALIFORNIA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021517209
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-09-27
Filing Date
2019-09-27
Publication Date
2024-11-29
Estimated Expiration
2039-09-27

AI Technical Summary

Technical Problem

There is a need for effective treatments to restore damaged photoreceptor cells and restore visual function in retinal degeneration, which often leads to blindness, as existing methods are inadequate in addressing the progressive decline and death of these cells.

Method used

A method is described for isolating primary retinal cells from human samples between 12 to 28 weeks of gestation, involving mechanical dissociation without protease digestion, followed by culturing these cells to generate non-immortal retinal progenitor cells, which can be administered to treat retinal diseases and improve visual function.

Benefits of technology

The method enhances cell viability and yield, reducing the risk of cell lysis and DNA leakage, and allows for the generation of non-immortal retinal progenitor cells that can restore and protect visual function, offering a clinically significant improvement in retinal health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591828000001
    Figure 0007591828000001
  • Figure 0007591828000002
    Figure 0007591828000002
Patent Text Reader

Abstract

Disclosed herein are compositions and methods for treating, ameliorating, or preventing retinal diseases or conditions by administering retinal progenitor cells; for improving light-adapted (daytime) vision; for improving corrected vision, for improving macular function, for improving visual fields, or for improving dark-adapted (nighttime) vision. The subject inventions described herein generally relate to the fields of stem cell biology and regenerative medicine. In an alternative embodiment, provided herein are methods for isolating primary retinal cells obtained or isolated from a human sample.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 62 / 737,622, filed September 27, 2018, the contents of which are incorporated by reference in their entirety.

[0002] Technical Field The subject inventions described herein generally relate to the fields of stem cell biology and regenerative medicine. In alternative embodiments, provided herein are methods for isolating primary retinal cells obtained or isolated from human samples. In alternative embodiments, compositions and methods are provided for treating, ameliorating, or preventing retinal diseases or conditions by administering retinal progenitor cells or by regenerating macular and / or scotopic visual function; for improving photopic (daytime) vision; improving visual acuity, improving macular function, improving visual field, or improving scotopic (nighttime) vision. [Background technology]

[0003] background Retinal degeneration refers to the deterioration or degeneration caused by the progressive and irreversible deterioration and death of retinal photoreceptor cells.The death of photoreceptor cells can lead to blindness.Therefore, there is a need in the art for effective treatments to restore damaged and lost photoreceptor cells and restore visual function. Summary of the Invention [Means for solving the problem]

[0004] overview The present disclosure provides a method for isolating primary retinal cells obtained or obtained from a human sample by (a) processing or having processed a obtained sample of human retinal tissue from a human between about 12 weeks and about 28 weeks of gestation, (b) mechanically dissociating the obtained sample, (c) determining the viability and quantity of primary retinal cells obtained from the sample, and (d) confirming or having confirmed the morphology of the obtained primary retinal cells to produce a suspension of dissociated cells and cell clusters.

[0005] In some embodiments of the disclosed methods, the human retinal tissue is obtained from one or a pair of human eyes. In some embodiments of the disclosed methods, the eyeball(s) have normal morphology, including intact globe(s), clear cornea, and / or normal shape. In some embodiments, immediately after organ harvest from the donor, the fetal eyeball (containing the human retinal tissue) is preserved in RPMI-1640 medium containing L-glutamine and stored on ice. In any of these methods, the preserved human retinal tissue is delivered and used within a specified period of time from harvest. In various embodiments, the human retinal tissue is shipped on ice and delivered within a shipping window. By way of non-limiting example, the transport window may range from about 1 to about 26 or more hours (e.g., 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16 , 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, or 26 hours), for example, about 4.5 to about 21.5 hours (e.g., 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, or 21.5) or about 7 to about 26 hours (e.g., 7, 7.5, 8, 8.5, 9, The time can be 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, or 26 hours).

[0006] In some embodiments of the disclosed method, processing the resulting sample of step (a) includes: (i) removing the eyeball(s) from RPMI-1640 medium after organ harvest and rinsing them 1 to 5 times (e.g., 1, 2, 3, 4, or 5 times) with ice-cold phosphate-buffered saline (PBS) supplemented with antibiotics; (ii) removing the optic nerve and mesenchymal tissue from the eyeball to remove all extraocular cells; (iii) rinsing the eyeball with ice-cold PBS supplemented with antibiotics; (iv) puncturing the limbus of the globe using a needle; (v) making a circumferential cut along the limbus with microsurgical scissors; (vi) removing the lens, cornea, and associated vitreous body; (vii) dissociating the retina(s) from the retinal pigment epithelium (RPE) layer to generate an isolated retina; and (viii) placing the isolated retina(s) in a Petri dish containing ice-cold medium or PBS supplemented with antibiotics.

[0007] In some embodiments of the disclosed method, the mechanical dissociation in step (b) comprises mechanically dissociating the retina(s) obtained in step (a) by: (i) transferring the retina(s) to a conical tube; (ii) mechanically dissociating the retina(s) to generate dissociated retina(s); (iii) washing the Petri dish with serum-free medium supplemented with antibiotics and transferring the medium containing any remaining dissociated retina(s) to the conical tube containing the dissociated retina(s); (iv) pelleting the dissociated retina(s) by centrifugation; and (v) removing the supernatant. In some embodiments, the mechanical dissociation of the retina is performed by trituration with a sterile pipette. In some embodiments, the dissociated retina is pelleted by centrifugation at about 10 to about 1000 × g for about 0 to about 30 minutes at 1 to 50°C.

[0008] In some embodiments of the disclosed methods, the step (c) of determining the viability and quantity of primary retinal cells comprises: (i) resuspending the pelleted retinal tissue from step (b) in ice-cold, antibiotic-supplemented serum-free medium; (ii) determining the quantity and viability of retinal cells and retinal cell clusters obtained from mechanical dissociation of the retinal tissue; (iii) seeding the cells into a fibronectin-coated cell culture flask or plate containing antibiotic-supplemented serum-free medium; and (iv) incubating the retinal cell-containing flask or plate at 10 to 50°C. In some embodiments, the quantity and viability of the cells are measured using an NC-200 cell counter. In some embodiments, the number of cells counted is about 1 to about 1,000,000,000 cells. In some embodiments, the percentage of viable cells counted is about 10 to about 100. In some embodiments, the flask or plate is seeded with about 1 to about 1,000,000,000 cells. In some embodiments, incubation of retinal cell-containing flasks or plates is at 37° C. under 0-30% CO 2 and 0-50% O 2 .

[0009] In some embodiments of the methods of the present disclosure, step (d) includes confirming that the retinal cells seeded onto the cell culture flask or plate consist of retinal cell clusters comprised of about 1 to about 100 cells.

[0010] In some embodiments of the disclosed methods, the antibiotic used to supplement the PBS or serum-free medium is gentamicin. In some embodiments, the antibiotic is used at a concentration of about 0 to about 10,000 μg / mL.

[0011] The present disclosure provides a method for isolating primary retinal cells from a human sample, the method comprising: (a) isolating a retinal sample comprising a plurality of primary retinal cells from the human sample, wherein the human sample is from a human donor between about 12 weeks and about 28 weeks of gestational age; (b) mechanically dissociating the plurality of primary retinal cells in the retinal sample isolated in step (a) without digesting the plurality of primary retinal cells with a protease, thereby producing a suspension of dissociated cells and cell clusters; and (c) determining the viability, quantity, and morphology of the primary retinal cells from the retinal sample, wherein the suspension comprises at least 30×10 6 and generating viable primary retinal cells of said retinal cells.

[0012] In some embodiments of the disclosed methods, the human sample is one or a pair of human eyeballs. In some embodiments, the eyeball(s) have normal morphology, including intact globe(s), clear cornea, normal shape, or any combination thereof. In some embodiments, prior to step (a), the human sample is placed in transport cell culture medium after collection from the human donor. In some embodiments, the transport cell culture medium comprises RPMI-1640 or Advanced DMEM / F12 containing L-glutamine. In some embodiments, the transport cell culture medium comprises about 0.5-50 micrograms of gentamicin per milliliter (mL), and optionally, the transport cell culture medium comprises about 50 micrograms of gentamicin per milliliter. In some embodiments, the human sample is stored at about 1-8°C, for example, by placing on ice, immediately after being placed in the transport cell culture medium.

[0013] In some embodiments of the disclosed methods, the human sample is used within about 7 to about 26 hours of collection from the human donor.

[0014] In some embodiments of the method of the present disclosure, isolating a retinal sample from a human sample in step (a) includes (i) removing one or a pair of human eyeballs from a transport culture medium; (ii) rinsing the one or a pair of human eyeballs with phosphate buffered saline (PBS) supplemented with antibiotics at about 1-8°C; (iii) removing the optic nerve and mesenchymal tissue from the one or a pair of human eyeballs; (iv) washing the one or a pair of human eyeballs with PBS supplemented with antibiotics at about 1-8°C; (v) using a needle to remove the retinal tissue from each of the one or a pair of human eyeballs. The method includes (i) drilling a hole in the margin of the body; (ii) making a circumferential incision along the margin of one or a pair of human eyes; (iii) removing the lens, cornea, and associated vitreous body from one or a pair of human eyes; (viii) dissociating the retina(s) from the retinal pigment epithelium (RPE) layer to generate an isolated retina or a pair of isolated retinas; and (ix) placing the isolated retina or a pair of isolated retinas in culture medium or PBS at about 1-8°C, wherein the culture medium or PBS is supplemented with antibiotics. In some embodiments, step (ii) is repeated 1-5 times or 3 times. In some embodiments, step (iii) removes some or all of the extraocular cells.

[0015] In some embodiments of the disclosed methods, mechanically dissociating the plurality of primary retinal cells in step (b) comprises (i) transferring the retinal sample to a tube, (ii) mechanically dissociating the retinal sample to generate a plurality of dissociated primary retinal cells, (iii) pelleting the plurality of dissociated primary retinal cells by centrifugation, and (iv) removing the supernatant. In some embodiments, mechanical dissociation of the retina is performed by trituration with a sterile pipette. In some embodiments, trituration is performed 2-50 times, 2-10 times, or 4-8 times. In some embodiments, the plurality of dissociated primary retinal cells is pelleted by centrifugation at about 140 × g for about 3 minutes at 4°C. In some embodiments, the method comprises washing the plurality of dissociated primary retinal cells with antibiotic-supplemented culture medium or PBS after step (ii) and before step (iii).

[0016] In some embodiments of the disclosed methods, the plurality of dissociated primary retinal cells comprises single cells and clusters of cells.

[0017] In some embodiments of the disclosed method, determining the viability, quantity, and morphology of primary retinal cells in step (c) includes (i) resuspending the pelleted primary retinal cells from step (b) in culture medium supplemented with antibiotics at about 1-8°C; (ii) seeding a plurality of dissociated retinal cells into one or more coated cell culture flasks or plates containing culture medium, optionally supplemented with antibiotics; (iii) incubating the plurality of dissociated retinal cells at 10-50°C, optionally at 37°C; and (iv) determining the quantity and viability of primary retinal cells and retinal cell clusters. In some embodiments, the quantity and viability of primary retinal cells are measured by agglutination cell counting, a hemocytometer, or an NC-200 cell counter using trypan blue. In some embodiments, the number of viable primary retinal cells is about 20 x 10 6 ~Approx. 1×10 9 of viable primary retinal cells, or approximately 73–147 × 10 6 In some embodiments, the percentage of viable counted cells is between about 10% and about 100%, or between about 68% and about 85%.

[0018] In some embodiments of the disclosed methods, the flask or plate is seeded with about 1 to about 1,000,000,000 cells in step (ii).

[0019] In some embodiments of the disclosed methods, the plurality of dissociated retinal cells are incubated at (1) about 37°C under 0-30% CO2 and 0-50% O2; (2) about 37°C, 5% or less CO2 and 20% or less O2; or (3) about 37°C, 5% or less CO2 and 3% or less O2. In some embodiments, the plurality of dissociated retinal cells are incubated at 37°C, 5% or less CO2 and 3% or less O2.

[0020] In some embodiments of the methods of the present disclosure, determining the viability, quantity, and morphology of the primary retinal cells in step (c) includes (i) visually inspecting the plurality of dissociated retinal cells under a microscope, and (ii) confirming that the plurality of retinal cells seeded into the cell culture flask or plate comprises clusters of retinal cell clusters consisting of about 2 to about 1,000 cells.

[0021] In some embodiments of the disclosed methods, the serum-free medium comprises (a) Advanced DMEM / F12, (b) N-2 supplement, (c) EGF (recombinant human epidermal growth factor), (d) bFGF (basic fibroblast growth factor), and / or (e) GlutaMAX I.

[0022] In some embodiments of the disclosed methods, the culture medium is serum-free. In some embodiments, the culture medium comprises complete medium. In some embodiments, the culture medium comprises Dulbecco's Modified Eagle's Medium (DMEM / F12), Advanced DMEM / F12, Knockout DMEM / F12, Neurobasal Medium, ReNcell, or Ultraculture Medium. In some embodiments, the culture medium comprises Advanced DMEM / F12. In some embodiments, the culture medium comprises N-2 supplements and GlutaMAX-I. In some embodiments, the culture medium comprises B27, B27 xeno-free, or Stempro. In some embodiments, the culture medium comprises a supplement or additive that supports cell survival or growth. In some embodiments, the supplement or additive that supports cell survival or growth is selected from the group consisting of L-glutamine, recombinant human epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), other growth factors, and combinations thereof. In some embodiments, the antibiotic comprises gentamicin at a concentration of about 0.5 to about 50 μg / mL, and optionally, the concentration of gentamicin is about 30 μg / mL.

[0023] The present disclosure provides a method for culturing isolated primary human retinal cells to generate a population of non-immortal human retinal progenitor cells, the method comprising: (a) culturing a suspension of isolated primary retinal cells in serum-free medium in culture flasks or plates coated with xeno-free fibronectin, ornithine, polylysine, or laminin at standard oxygen levels for about 4-6 passages; (b) subsequently culturing the suspension in serum-free medium at reduced oxygen levels for about 3-6 additional passages, wherein the cells are passaged at 40%-90% confluence, and at each passage, treating with an enzyme to dissociate the cells and adding fresh culture medium; and (c) subsequently cryopreserving the cells, thereby generating a population of non-immortal human retinal progenitor cells.

[0024] In some embodiments of the disclosed methods, after the subsequent step of culturing the suspension at low oxygen levels, the cells are grown at normal oxygen levels for a period of time without passaging the cells. In some embodiments, the period between passagings is 3 to 5 days (e.g., 3, 4, or 5 days).

[0025] In some embodiments of the disclosed methods, the enzyme solution used to dissociate the cells comprises trypsin or an equivalent. In some embodiments, the cells are dissociated at the first passage using an enzyme solution comprising trypsin or an equivalent and EDTA at a ratio of about 1:4. In some embodiments, at the first passage, the trypsin or equivalent and EDTA are at a ratio of about 1:3, 1:3.1, 1:3.2, 1:3.3, 1:3.4, 1:3.5, 1:3.6, 1:3.7, 1:3.8, 1:3.9, 1:4.0, 1:4.1, 1:4.2, 1:4.3, 1:4.4, 1:4.5, 1:4.6, 1:4.7, 1:4.8, 1:4.9, or 1:5.0. In some embodiments, the cells are dissociated at the first passage using an enzyme solution comprising trypsin or equivalent, EDTA, and DPBS in a ratio of about 1:1:3. In some embodiments, at the first passage, the trypsin or equivalent, EDTA, and DPBS are in a ratio of about 1:1:2, 1:1:2.1, 1:1:2.2, 1:1:2.3, 1:1:2.4, 1:1:2.5, 1:1:2.6, 1:1:2.7, 1:1:2.8, 1:1:2.9, 1:1:3.0, 1:1:3.1, 1:1:3.2, 1:1:3.3, 1:1:3.4, 1:1:3.5, 1:1:3.6, 1:1:3.7, 1:1:3.8, 1:1:3.9, or 1:1:4.0. In some embodiments, the cells are dissociated in the first passage for 6-10 minutes at about 37° C. In some embodiments, the cells are dissociated in the second passage using an enzyme solution comprising trypsin or equivalent, EDTA, and DPBS in a ratio of about 1:1:3. In some embodiments, at the second passage, the trypsin or equivalent, EDTA, and DPBS are in a ratio of about 1:1:2, 1:1:2.1, 1:1:2.2, 1:1:2.3, 1:1:2.4, 1:1:2.5, 1:1:2.6, 1:1:2.7, 1:1:2.8, 1:1:2.9, 1:1:3.0, 1:1:3.1, 1:1:3.2, 1:1:3.3, 1:1:3.4, 1:1:3.5, 1:1:3.6, 1:1:3.7, 1:1:3.8, 1:1:3.9, or 1:1:4.0. In some embodiments, at the second passage, the cells are dissociated using an enzyme solution comprising trypsin or equivalent and EDTA in a ratio of about 1:1.In some embodiments, at the second passage, trypsin or an equivalent and EDTA are in a ratio of about 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, or 1:1.5. In some embodiments, the cells are dissociated at about 37°C for 4-8 minutes at the second passage. In some embodiments, the cells are dissociated at the third passage and all further passages using an enzyme solution comprising trypsin or an equivalent and EDTA in a ratio of about 1:1. In some embodiments, at the third and all further passages, trypsin or an equivalent and EDTA are in a ratio of about 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, or 1:1.5. In some embodiments, cells are dissociated for 4-8 minutes at 37°C for the third and all further passages. In some embodiments, trypsin or equivalent includes TrypLE, e.g., TrypLE Express or TrypLE Select. In some embodiments, dissociation is stopped by the addition of excess DMEM or PBS. In some embodiments, cell number and viability are determined after dissociation. In some embodiments, cell number and viability are determined using an NC-200 cell counter.

[0026] The present disclosure provides a method for culturing isolated primary human retinal cells to generate a population of non-immortal human retinal progenitor cells, comprising the steps of: (a) seeding a plurality of primary retinal cells generated by the methods described herein into one or more coated culture flasks or plates containing culture medium at a first passage to generate a plurality of cultured retinal cells; (b) seeding the plurality of cultured retinal cells generated by the first passage into one or more coated culture flasks or plates containing culture medium at a second passage; (c) seeding the plurality of cultured retinal cells generated by the second passage into one or more coated culture flasks or plates containing culture medium at a third passage; and (d) cryopreserving the plurality of cultured retinal cells, wherein the one or more coated culture flasks or plates have an area of ​​less than 1 square centimeter (cm). 2 ) approximately 1 × 10 4 1 cm from the cell 2 Approximately 2 x 10 6 The cells are seeded at a density of 100-1500 μg / ml, where the seeding density of the first passage is greater than the seeding density of the second passage, and the seeding density of the second passage is greater than the seeding density of the third passage, thereby providing a method of generating a population of non-immortal human retinal progenitor cells.

[0027] In some embodiments of the disclosed methods, the method further comprises seeding a plurality of cultured retinal cells generated by the immediately preceding passage onto one or more coated culture flasks or plates containing culture medium for one or more further passages.

[0028] In some embodiments of the disclosed methods, the culture flasks or plates are coated with xeno-free fibronectin, ornithine, polylysine, laminin, or a combination thereof.

[0029] In some embodiments of the disclosed methods, the plurality of primary or cultured retinal cells are cultured at (1) about 37°C under 0-30% CO2 and 0-50% O2; (2) about 37°C, 5% or less CO2, and 20% or less O2; or (3) about 37°C, 5% or less CO2, and 3% or less O2. In some embodiments, the plurality of primary or cultured retinal cells are cultured at about 37°C, 5% or less CO2, and 3% or less O2. In some embodiments, the period between two directly successive passages is 2-8 days, 3-6 days, 4-5 days, or 3-4 days. In some embodiments, the period between two directly successive passages is 3-4 days.

[0030] In some embodiments of the disclosed methods, the plurality of primary retinal cells are dissociated at a first passage with a first enzyme solution comprising (1) trypsin or an equivalent and ethylenediaminetetraacetic acid (EDTA), or (2) trypsin or an equivalent, EDTA, and DPBS. In some embodiments, the trypsin equivalent is TrypLE. In some embodiments, (1) TrypLE and EDTA are in a 1:4 ratio in the first enzyme solution, or (2) TrypLE, EDTA, and DPBS are in a 1:1:3 ratio. In some embodiments, the plurality of primary retinal cells are dissociated at about 37°C for about 5-20 minutes, about 6-10 minutes, or about 7-8 minutes. In some embodiments, the plurality of primary retinal cells are dissociated at about 37°C for about 7-8 minutes.

[0031] In some embodiments of the disclosed methods, the plurality of cultured retinal cells are dissociated at the second passage with a second enzyme solution comprising (1) trypsin or an equivalent, EDTA, and DPBS, or (2) trypsin or an equivalent, and DPBS. In some embodiments, the trypsin equivalent is TrypLE. In some embodiments, (1) TrypLE, EDTA, and DPBS are in a 1:1:3 ratio in the second enzyme solution, or (2) TrypLE and DPBS are in a 1:1 ratio in the second enzyme solution. In some embodiments, the plurality of cultured retinal cells are dissociated at about 37°C for about 5-20 minutes, about 6-10 minutes, or about 7-8 minutes. In some embodiments, the plurality of cultured retinal cells are dissociated at about 37°C for about 5-6 minutes.

[0032] In some embodiments of the disclosed methods, the plurality of cultured retinal cells are dissociated at least at a third or further passage with a third enzyme solution comprising trypsin or an equivalent and DPBS. In some embodiments, the trypsin equivalent comprises TrypLE. In some embodiments, the TrypLE and DPBS are in a 1:1 ratio in the third enzyme solution. In some embodiments, the plurality of cultured retinal cells are dissociated at least at a third or further passage for about 5-10 minutes or about 5-7 minutes at about 37°C. In some embodiments, the at least a third or further passage comprises 3-5 passages.

[0033] In some embodiments of the disclosed methods, the method includes determining the number and viability of cells after dissociation of the plurality of cultured retinal cells after the second passage, in some embodiments, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells are viable.

[0034] In some embodiments of the disclosed methods, the cells are cultured in a culture flask or plate at a density of about 0.5×10 6 to approximately 3.0 × 10 6 cells / cm 2 , and approximately 0.1 × 10 at the second passage. 6to approximately 0.5 × 10 6 cells / cm 2 , and approximately 0.03 × 10 at the third passage. 6 to approximately 0.2 × 10 6 cells / cm2, and at the fourth and further passages at a density of about 10,000 to about 60,000 cells / cm2.

[0035] The present disclosure provides a method for cryopreserving retinal progenitor cells generated using the methods of the present disclosure, the method including: (i) enzymatically dissociating the cells using trypsin; (ii) stopping the dissociation with an excess amount of culture medium or Advanced DMEM / F12; (iii) centrifuging the cells at 10×g to 10,000×g for 1 to 30 minutes; (iv) resuspending the cells in culture medium and determining total cell number and viability; (v) adding cryopreservation medium to achieve a final dimethyl sulfoxide (DMSO) concentration of 5 to 30%; (vi) aliquoting cells into individual cryovials; (vii) freezing each vial using a controlled rate freezer; and (viii) placing each vial of cells in liquid N2.

[0036] In some embodiments of the disclosed method, the cryopreservation step comprises: (a) enzymatically dissociating the cells using 1:1 trypsin or equivalent and DPBS; (b) stopping the dissociation with excess DMEM or PBS; (c) pelleting the cells via centrifugation at 10-10,000 g for 1-30 minutes; (d) resuspending the cells in serum-free medium and determining total cell number and viability; (e) adding cryopreservation medium to achieve a final DMSO concentration of 5-30%; and (f) distributing 0.2-100×10 cells / ml of each cryovial. 6 This is performed by aliquoting the cells, (g) freezing each vial at -80 °C for 6 to 72 hours, and (h) placing each vial of cells into liquid N2.

[0037] In some embodiments of the cryopreservation method of the present disclosure, the trypsin equivalent in step (i) comprises TrypLE. In some embodiments, the cryopreservation medium comprises culture medium and 10% DMSO. In some embodiments, the plurality of cells in step (vi) is about 0.5 x 10 cells per cryovial. 6 ~50×10 6 cells, or approximately 0.5 x 10 per mL of culture medium and DMSO 6 ~Approx. 20×10 6 It is a cell.

[0038] In some embodiments of the disclosed methods, the cells and / or cell clusters are cultured with a supplement or additive that supports cell survival or growth. In some embodiments, the supplement or additive that supports cell survival or growth is selected from the group consisting of L-glutamine, human recombinant growth factors consisting of EGF and bFGF (Invitrogen), and other growth factors.

[0039] In an alternative embodiment, there is provided a pharmaceutical composition comprising a retinal progenitor cell or a population or plurality of non-immortal human retinal progenitor cells isolated by a method according to any preceding claim, and optionally also comprising a pharmaceutically acceptable excipient.

[0040] In an alternative embodiment, provided herein is a kit comprising a retinal progenitor cell or a population of non-immortal human retinal progenitor cells or a plurality of non-immortal human retinal progenitor cells isolated by a method according to any of the preceding claims.

[0041] In alternative embodiments, there is provided a method for treating, ameliorating or preventing a retinal disease or condition, improving photopic (daytime) vision, improving corrected vision, improving macular function, improving visual field, or improving scotopic (night) vision, comprising: (a) administering or having administered to an individual in need thereof a retinal progenitor cell or a population of non-immortal human retinal progenitor cells or a plurality of non-immortal human retinal progenitor cells isolated by the method of any preceding claim; or (b)(i) providing or having provided a retinal progenitor cell or a population of non-immortal human retinal progenitor cells or a plurality of non-immortal human retinal progenitor cells isolated by the method of any preceding claim; and (ii) administering or having administered to an individual in need thereof a retinal progenitor cell or a population of non-immortal human retinal progenitor cells or a plurality of non-immortal human retinal progenitor cells.

[0042] In an alternative embodiment, there is provided the use of a retinal progenitor cell or a population or plurality of non-immortal human retinal progenitor cells isolated by a method according to any preceding claim in the manufacture of a medicament for treating, ameliorating or preventing a retinal disease or condition, for improving light-adapted (daytime) vision, for improving corrected vision, for improving macular function, for improving visual field, or for improving dark-adapted (nighttime) vision.

[0043] In an alternative embodiment, there is provided a retinal progenitor cell or a population or plurality of non-immortal human retinal progenitor cells isolated by a method according to any preceding claim for use in treating, ameliorating or preventing a retinal disease or condition, improving light-adapted (daytime) vision, improving corrected vision, improving macular function, improving visual field or improving dark-adapted (nighttime) vision.

[0044] Any of the above aspects may be combined with any other aspect of the present disclosure. In certain embodiments, for example, the following are provided: (Item 1) 1. A method for isolating primary retinal cells from a human sample, comprising: (a) isolating a retinal sample comprising a plurality of primary retinal cells from the human sample, wherein the human sample is from a human donor between about 12 weeks and about 28 weeks of gestation; (b) mechanically dissociating the plurality of primary retinal cells in the retinal sample isolated in step (a) without digesting the plurality of primary retinal cells with a protease, thereby producing a suspension of dissociated cells and cell clusters; (c) determining the viability, quantity and morphology of the primary retinal cells obtained from the retinal sample, 6 The steps by which viable primary retinal cells are generated A method comprising: (Item 2) Item 10. The method of item 1, wherein the human sample is one or a pair of human eyeballs. (Item 3) Item 3. The method of item 2, wherein the eyeball(s) have normal morphology including intact sphere(s), clear cornea, normal shape or any combination thereof. (Item 4) 4. The method according to any one of items 1 to 3, wherein prior to step (a), the human sample is placed in transport cell culture medium after collection from the human donor. (Item 5) 5. The method of claim 4, wherein the transport cell culture medium comprises RPMI-1640 or Advanced DMEM / F12 containing L-glutamine. (Item 6) 6. The method of claim 4 or 5, wherein the transport cell culture medium comprises about 0.5 to 50 micrograms of gentamicin per milliliter, and optionally, the transport cell culture medium comprises 50 micrograms of gentamicin per milliliter. (Item 7) 7. The method according to any one of items 1 to 6, wherein the human sample is stored at about 1 to 8° C. immediately after being placed in the transport cell culture medium. (Item 8) 8. The method according to any one of items 1 to 7, wherein the human sample is used within about 7 to about 26 hours of collection from the human donor. (Item 9) isolating the retinal sample from the human sample in step (a) (i) removing said one or pair of human eyes from said transport culture medium; (ii) rinsing the one or pair of human eyes with phosphate buffered saline (PBS) supplemented with antibiotics at about 1-8°C; (iii) removing the optic nerve and mesenchymal tissue from said one or pair of human eyes; (iv) washing the one or pair of human eyes with PBS supplemented with antibiotics at about 1-8°C; (v) using a needle to puncture the rim of the globe of each of said one or a pair of human eyes; (vi) cutting circumferentially along the edge of said one or pair of human eyes; (vii) removing the lens, cornea, and associated vitreous body from said one or pair of human eyes; (viii) dissociating the retina(s) from the retinal pigment epithelium (RPE) layer to generate an isolated retina or a pair of isolated retinas; and (ix) placing the isolated retina or a pair of isolated retinas in culture medium or PBS at about 1 to 8°C, wherein the culture medium or PBS is supplemented with an antibiotic. (Item 10) Item 10. The method according to item 9, wherein step (ii) is repeated 1 to 5 times or 3 times. (Item 11) 11. The method of claim 9 or 10, wherein step (iii) removes some or all of the extraocular tissues and cells. (Item 12) Step (b) (i) transferring the retinal sample to a tube; (ii) mechanically dissociating the retinal sample to generate a plurality of dissociated primary retinal cells; (iii) pelleting a plurality of the dissociated primary retinal cells by centrifugation; and (iv) Removing the supernatant 12. The method according to any one of items 1 to 11, comprising: (Item 13) 13. The method of item 12, wherein said mechanical dissociation of the retina is carried out through trituration with a sterile pipette. (Item 14) Item 14. The method according to item 13, wherein the grinding is carried out 2 to 50 times, 2 to 10 times, or 4 to 8 times. (Item 15) 15. The method of any one of items 12-14, wherein the plurality of dissociated primary retinal cells are pelleted by centrifugation at about 140×g for about 3 minutes at 4° C. (Item 16) 16. The method of any one of items 12 to 15, comprising washing the plurality of dissociated primary retinal cells with antibiotic-supplemented culture medium or PBS after step (ii) and before step (iii). (Item 17) 17. The method of any one of items 12 to 16, wherein the plurality of dissociated primary retinal cells comprises single cells and clusters of cells. (Item 18) Step (c) (i) resuspending the pelleted primary retinal cells from step (b) in antibiotic-supplemented culture medium at about 1-8°C; (ii) seeding a plurality of said dissociated retinal cells into one or more coated cell culture flasks or plates containing a culture medium, wherein optionally said cell culture medium is supplemented with antibiotics; (iii) incubating the plurality of dissociated retinal cells at 10-50°C, optionally wherein the incubation is at 37°C; and (iv) determining the quantity and viability of primary retinal cells and retinal cell clusters; 18. The method according to any one of items 1 to 17, comprising: (Item 19) 19. The method of item 18, wherein the quantity and viability of primary retinal cells are measured by agglutination cell counting, a hemocytometer, or an NC-200 cell counter using trypan blue. (Item 20) The number of viable primary retinal cells is approximately 20 × 10 6 ~Approx. 1×10 9 of viable primary retinal cells, or approximately 73–147 × 10 6 20. The method of claim 19, wherein the cells are viable primary retinal cells. (Item 21) 21. The method of any one of items 18 to 20, wherein the percentage of viable counted cells is about 10% to about 100%, or about 68% to about 85%. (Item 22) 22. The method of any one of items 18 to 21, wherein the flask is seeded with about 1 to about 1,000,000,000 cells in step (ii). (Item 23) A plurality of dissociated retinal cells (1) 0-30% CO 2 and 0–50% O 2 Below 37℃, (2) 37°C, 5% or less CO 2 and 20% or lower O2 ;or (3) 37°C, 5% or less CO 2 and 3% or lower O 2 23. The method according to any one of items 18 to 22, wherein the culture medium is incubated with (Item 24) Step (c) (i) visually examining a plurality of said dissociated retinal cells under a microscope; and (ii) confirming that the plurality of retinal cells seeded in the cell culture flask or plate contains retinal cell clusters consisting of about 2 to about 1,000 cells; 24. The method according to any one of items 1 to 23, comprising: (Item 25) 1. A method for culturing isolated primary human retinal cells to generate a population of non-immortal human retinal progenitor cells, comprising: (a) seeding a plurality of primary retinal cells produced by the method of any one of items 1 to 24 into one or more coated culture flasks or plates containing a culture medium at a first passage to produce a plurality of cultured retinal cells; (b) seeding a plurality of cultured retinal cells generated in the first passage into one or more coated culture flasks or plates containing a culture medium at a second passage; (c) seeding a plurality of cultured retinal cells generated at the second passage into one or more coated culture flasks or plates containing a culture medium at the third passage; (d) cryopreserving a plurality of said cultured retinal cells; Including, The coated culture flask or flasks may have an area of ​​1 square centimeter (cm 2 ) approximately 0.5 × 10 4 1 cm from the cell 2 Approximately 5 x 10 6 Cells are seeded at a density of the seeding density of the first passage is greater than the seeding density of the second passage; and the seeding density of the second passage is greater than the seeding density of the third passage; Thereby generating said population of non-immortal human retinal progenitor cells. (Item 26) 26. The method of claim 25, further comprising the step of seeding a plurality of cultured retinal cells generated by the previous passage onto one or more coated culture flasks or plates containing culture medium for one or more additional passages. (Item 27) 28. The method according to any one of items 18 to 27, wherein the culture flask or plate is coated with xeno-free fibronectin, ornithine, polylysine, laminin, or a combination thereof. (Item 28) a plurality of the primary retinal cells or the cultured retinal cells, (1) 0-30% CO 2 and 0–50% O 2 Below 37℃, (2) 37°C, 5% or less CO 2 and 20% or lower O 2 ;or (3) 37°C, 5% or less CO 2 and 3% or lower O 2 28. The method according to any one of items 25 to 27, wherein the strain is cultured in a medium containing 100 kJ / ml. (Item 29) 29. The method according to any one of items 25 to 28, wherein the period between passaging is 2 to 8 days, 3 to 6 days, 4 to 5 days, or 3 to 4 days. (Item 30) The plurality of primary retinal cells are cultured at the first passage, (1) trypsin or equivalent and ethylenediaminetetraacetic acid (EDTA), or (2) Trypsin or equivalent, EDTA, and DPBS 30. The method according to any one of items 25 to 29, wherein the cellulose is dissociated with a first enzyme solution comprising: (Item 31) 31. The method of claim 30, wherein the trypsin equivalent is TrypLE. (Item 32) 32. The method of claim 31, wherein (1) the TrypLE and EDTA are in a ratio of 1:4 in the first enzyme solution, or (2) the TrypLE, EDTA, and DPBS are in a ratio of 1:1:3. (Item 33) 33. The method of any one of items 25 to 32, wherein the plurality of primary retinal cells is dissociated at 37°C for about 5 to 20 minutes, 6 to 10 minutes, or about 7 to 8 minutes. (Item 34) a plurality of the cultured retinal cells at the second passage; (1) trypsin or equivalent, EDTA and DPBS, or (2) Trypsin equivalent and DPBS 34. The method according to any one of items 25 to 33, wherein the cellulose is dissociated with a second enzyme solution comprising: (Item 35) 35. The method of claim 34, wherein the trypsin equivalent is TrypLE. (Item 36) 36. The method of claim 35, wherein (1) the TrypLE, EDTA, and DPBS are in a ratio of 1:1:3 in the second enzyme solution, or (2) the TrypLE and DPBS are in a ratio of 1:1 in the second enzyme solution. (Item 37) 37. The method of any one of items 34 to 36, wherein the plurality of cultured retinal cells is dissociated at 37° C. for about 5 to 20 minutes, about 6 to 10 minutes, or about 7 to 8 minutes. (Item 38) 38. The method of any one of items 26 to 37, wherein the plurality of cultured retinal cells in the third or further passage are dissociated with a third enzyme solution comprising trypsin or equivalent and DPBS. (Item 39) 39. The method of claim 38, wherein the trypsin equivalent comprises TrypLE. (Item 40) 40. The method of claim 39, wherein the TrypLE and the DPBS are in a 1:1 ratio in the third enzyme solution. (Item 41) 41. The method of any one of items 38 to 40, wherein the plurality of cultured retinal cells are dissociated at least in the third or further passage at 37° C. for about 5 to 10 minutes or about 5 to 7 minutes. (Item 42) 42. The method of any one of items 38 to 41, wherein the further passaging comprises two passages. (Item 43) 43. The method of any one of items 25 to 42, comprising determining cell number and viability after dissociation of a plurality of the retinal cells after the second passage. (Item 44) 44. The method of item 43, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the cells are viable. (Item 45) At the first passage, approximately 0.5 x 10 6 to approximately 3.0 × 106 cells / cm 2 , and about 0.1 x 10 at the second passage 6 to approximately 0.5 × 10 6 cells / cm 2 , and about 0.03 x 10 at the third passage. 6 to approximately 0.2 × 10 6 cells / cm 2 , and about 10,000 to about 60,000 cells / cm at the fourth and further passages. 2 44. The method according to any one of items 25 to 43, wherein the cells are seeded in a culture flask or plate at a density of (Item 46) The cryopreservation of step (d) (i) enzymatically dissociating said cells using trypsin or equivalent; (ii) stopping the dissociation with an excess of the culture medium or Advanced DMEM / F12; (iii) centrifuging the cells at 10×g to 10,000×g for 1 to 30 minutes; (iv) resuspending the cells in culture medium and determining total cell number and viability; (v) adding cryopreservation medium to achieve a final dimethyl sulfoxide (DMSO) concentration of 5–30%; (vi) aliquoting multiple cells into each cryovial; (vii) freezing each vial using a controlled rate freezer; and (viii) Fill each vial of cells with liquid N 2 Put in 46. ​​The method according to any one of items 25 to 45, comprising: (Item 47) 47. The method of any one of items 8 to 46, wherein the culture medium is serum-free. (Item 48) 48. The method of any one of items 8 to 47, wherein the culture medium comprises complete medium. (Item 49) 48. The method of any one of items 8 to 47, wherein the culture medium comprises Dulbecco's Modified Eagle's Medium DMEM / F12, Advanced DMEM / F12, Knockout DMEM / F12, Neurobasal medium, ReNcell or Ultraculture medium. (Item 50) 48. The method of any one of items 8 to 47, wherein the culture medium comprises Advanced DMEM / F12. (Item 51) 51. The method of item 49 or 50, wherein the culture medium comprises N-2 supplement and GlutaMAX-I. (Item 52) 52. The method of any one of items 49 to 51, wherein the culture medium comprises B27, B27 xeno-free or StemPro. (Item 53) 53. The method of any one of items 49 to 52, wherein the culture medium comprises a supplement or additive that supports cell survival or growth. (Item 54) 54. The method of claim 53, wherein the supplement or additive that supports cell survival or growth is selected from the group consisting of L-glutamine, recombinant human epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), other growth factors, and combinations thereof. (Item 55) 55. The method according to any one of items 8 to 54, wherein the antibiotic comprises gentamicin at a concentration of about 0.5 to about 50 μg / mL, optionally wherein the concentration of gentamicin is about 30 μg / mL. (Item 56) 47. The method of claim 46, wherein the trypsin equivalent in step (i) comprises TrypLE. (Item 57) 57. The method of any one of items 46 to 56, wherein the cryopreservation medium comprises culture medium and 10% DMSO. (Item 58) The plurality of cells of step (vi) is about 0.5 x 10 cells per mL of culture medium and DMSO. 6 From about 20 x 10 6 58. The method of any one of items 46 to 57, comprising cells. [Brief explanation of the drawings]

[0045] [Figure 1] Figure 1 is a line graph showing the average number of retina progenitor cells at each passage. Retinal progenitor cells were isolated from ocular samples using either Protocol A or Protocol B and processed on the same day (7 hours, 8 hours) or after overnight transport (24 hours). P means passage number, and d means days. Data points represent a theoretical calculation of the average number of retina progenitor cells for all retinal progenitor cells isolated using the same protocol and cultured under the same conditions.

[0046] [Figure 2] Figure 2 is a table listing the experimental and passaging conditions using Protocol B and comparing them with the previous culture method (Protocol A). P means passage number, d means days, T means TrypLE Select (Invitrogen), E means EDTA (Invitrogen), and P means Dulbecco's phosphate-buffered saline, or DPBS (Invitrogen). DETAILED DESCRIPTION OF THE INVENTION

[0047] Detailed Description When fetal eyes (and associated retinal tissue) are transported over long distances on ice, transport times can be quite long. During this time, the retinal tissue becomes increasingly fragile, gradually reducing the potential viability of the constituent cells. This poses a challenge for cell manufacturing when tissue must be sourced from a remote location, as the final product yield (at any given time in culture) is affected by the number of viable cells obtained per retina. However, the increased tissue fragility can be exploited to eliminate certain steps otherwise utilized in retinal cell isolation. In particular, the use of trypsin to disrupt retinal tissue can be eliminated, as the tissue can be disrupted with only gentle trituration. This is easier to perform and shortens the time from tissue to incubator. Furthermore, the use of EDTA during early passages also reduces stress on the cells during this critical period as they recover in culture. By breaking the retina into progressively smaller chunks over successive passages and not attempting to dissociate into single cells until later in the process, viability is further enhanced and the process becomes less risky. As cell viability improves, trypsin can be systematically introduced into the passaging process without negatively impacting yield.

[0048] In particular, expected cell yields may be adversely affected when the starting tissue is subjected to substantially longer transport times than previously. While tissue variations may be difficult to address directly, isolation and initial cell culture protocols can be modified to eliminate sources of cell loss and thereby increase final yields.

[0049] The methods for isolating retinal cells described herein have several advantages over previous methods when there is a long gap between tissue procurement and initiation of tissue culture. The methods described herein have advantages including, but not limited to, (1) improved yield, (2) ease of implementation due to elimination of enzymatic steps, (3) lower risk of cell lysis and DNA spillage with cell loss, (4) a faster process from tissue isolation to incubator, and (5) improved cell viability during early passages.

[0050] definition To facilitate understanding of this disclosure, several terms are defined below. These terms are used to describe specific embodiments of the subject invention described herein, but their use does not limit the subject invention except as outlined in the claims.

[0051] Any of the aspects and embodiments described herein can be combined with any other aspect or embodiment disclosed herein.

[0052] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this invention belongs.Other probes, compositions, methods and kits similar or equivalent to those described herein can be used in the implementation of this disclosure, but exemplary materials and methods are described herein.It should be understood that the terms used herein are only for the purpose of describing specific embodiments and are not limiting.

[0053] In this disclosure, the words "comprises," "comprising," "containing," "having," and the like can have the meaning ascribed to them in U.S. patent law and can mean "includes," "including," and the like; the terms "consisting essentially of" or "consisting essentially of" likewise have the meaning under U.S. patent law, and these terms are open-ended, allowing for the presence of more than what is recited so long as the basic or novel characteristics of the recited items are not altered by the presence of more than what is recited, but precludes prior art embodiments.

[0054] Unless specifically stated otherwise or clear from context, as used herein, the terms "a," "an," and "the" are understood to be singular or plural.

[0055] Unless specifically stated otherwise or clear from the context, as used herein, the term "or" is understood to be inclusive.

[0056] As used herein in other contexts, the term "about" refers to + / -10%, + / -9%, + / -8%, + / -7%, + / -6%, + / -5%, + / -4%, + / -3%, + / -2% or + / -1% of the recited value, e.g., amount, dose, temperature, time, percentage, etc., unless otherwise indicated.

[0057] As used herein, the terms "patient" or "subject" and the like are used interchangeably herein and refer to any mammal, including humans, domestic animals and farm animals, as well as zoo animals, sport animals and pet animals, such as dogs, horses, cats, and agricultural animals including cows, sheep, pigs and goats. One exemplary mammal is a human, including adults, children and the elderly. The subject may also be a pet animal, including dogs, cats and horses. Exemplary agricultural animals include cows and goats.

[0058] As used herein, the terms "treat," "treating," "treatment," and the like, unless otherwise indicated, refer to curing, reversing, alleviating, mitigating, minimizing, inhibiting the course of, suppressing, halting, and / or preventing the disease, disorder, or condition to which such term applies, or one or more (i.e., not necessarily all) symptoms of such disease, disorder, or condition, and include administration of any of the compositions, pharmaceutical compositions, or dosage forms described herein to prevent the onset of symptoms or complications, alleviate symptoms or complications, reduce the progression of, and / or eliminate, the disease, condition, or disorder. In alternative embodiments, treatment is therapeutic or ameliorating.

[0059] As used herein, "preventing" or "prevention" means to prevent, in whole or in part, or ameliorate, or control, or reduce or arrest the production or occurrence of, the thing or event to be prevented, e.g., a disease, disorder, or condition.

[0060] As used herein, the terms "purified" or "enriched" and the like refer to cells or cell populations that have been removed from their normal tissue environment and are present at higher concentrations than in the normal tissue environment. Thus, a "purified" or "enriched" cell population may further contain cell types other than retinal progenitor cells and may contain additional tissue components, and the terms "purified" or "enriched" do not necessarily refer only to the presence of progenitor cells or exclude the presence of other cell types.

[0061] In some embodiments, the retinal progenitor cell populations disclosed herein are at least 5% pure, at least 10% pure, at least 15% pure, at least 20% pure, at least 25% pure, at least 30% pure, at least 35% pure, at least 40% pure, at least 45% pure, at least 50% pure, at least 55% pure, at least 60% pure, at least 65% pure, at least 70% pure, at least 75% pure, at least 80% pure, at least 85% pure, at least 90% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, or any increment between 5% and 99% pure (e.g., 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 65%, 70%, 75%, 80%, 85%, 90% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, or any increment between ,16%,17%,18%,19%,20%,21%,22%,23%,24%,25%,26%,27%,28%,29%,30%,31%,32%,33%,34%,35%,36%,37%,38%,39%,40%,41%,42%,43%,44%,45%,46%,47%,48%,49%,50%,51%,52%,53%,54%,55%,56%,57%,58%,59% , 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% retinal progenitor cells).

[0062] "Marker" refers to any molecule that can be observed or detected. For example, markers can include, but are not limited to, nucleic acids, such as transcripts of a particular gene, polypeptide products of a gene, non-gene product polypeptides, glycoproteins, carbohydrates, glycolipids, lipids, lipoproteins, or small molecules (e.g., molecules having a molecular weight of less than 10,000 daltons). In alternative embodiments, retinal progenitor cells can be characterized by the presence of one or more markers that can be expressed on the surface of cells within a cell population ("cell surface markers"), within cells within a cell population (i.e., in the nuclei or cytoplasm of the cells), and / or expressed at the RNA or protein level as "gene" markers.

[0063] As used herein, the terms "express" and "expression" refer to the transcription and / or translation of a nucleic acid sequence in a host cell. The level of expression of a desired product / protein of interest, e.g., a marker, in a host cell can be determined or "screened" based on the amount of corresponding mRNA present in the cell, or, as in this example, the amount of the desired polypeptide / protein of interest encoded by the selected sequence. For example, mRNA transcribed from a selected sequence can be quantified or detected by Northern blot hybridization, ribonuclease RNA protection, in situ hybridization to cellular RNA, microarray analysis, or reverse transcription-polymerase chain reaction (RT-PCR). The protein encoded by a selected sequence can be detected or quantified by various antibody-based methods, such as ELISA, Western blot, radioimmunoassay, immunoprecipitation, testing for protein biological activity, immunostaining of the protein (including, e.g., immunohistochemistry and immunocytochemistry), flow cytometry or fluorescence-activated cell sorting ("FACS") analysis, or homogeneous time-resolved fluorescence (HTRF) assays. Retinal progenitor cells (RPCs)

[0064] The isolation, characterization and use of mammalian retinal progenitor cells is described in detail in WO2012 / 158910, the contents of which are incorporated herein by reference in their entirety.

[0065] During vertebrate embryonic development, the retina and optic nerve arise as outgrowths of the developing brain, and as such, the retina is considered part of the central nervous system (CNS) and is indeed brain tissue. The retina is a layered structure with several layers of neurons interconnected by synapses. From nearest to furthest from the vitreous, i.e., from nearest the anterior lateral part of the head to the interior and posterior part of the head, the retinal layers include: (1) the inner limiting membrane, which contains the Muller cell footplates; (2) the nerve fiber layer, which contains the axons of ganglion cell nuclei; (3) the ganglion cell layer, which contains the nuclei of ganglion cells, whose axons become optic nerve fibers; (4) the inner plexiform layer, which contains the synapses between bipolar cell axons and the dendrites of ganglion and amacrine cells; (5) the inner nuclear layer, which contains the nuclei and peripheral cell bodies (perikarya) of bipolar cells; (6) the outer plexiform layer, which contains the processes of rods and cones, which terminate in the rod globules and cone stalks, respectively; (7) the outer nuclear layer, which contains the cell bodies of rods and cones; (8) the outer limiting membrane, which separates the inner segments of photoreceptors from their nuclei; (9) the photoreceptor layer; and (10) the retinal pigment epithelium (RPE), which is a single layer of cuboidal cells. Neurons that are directly sensitive to light are photoreceptor cells, which consist of two main types: rods and cones. Rods function primarily in dim light and provide black-and-white vision, while cones support daytime vision and color perception. A third type of photoreceptor, the light-sensitive ganglion cells, is important for reflex responses to bright sunlight.

[0066] Donor fetal retinal cells (e.g., retinal progenitor cells described herein) can have a trophic effect on the host retina, particularly the host cones. This trophic effect is not only neuroprotective but also has a rapid, restorative effect on remaining host retinal cells, as determined by improved visual function. The donor cells can integrate with the retina and replace photoreceptors (which may be limited in number) through cellular differentiation. The overall effect is to rapidly and sustainably restore and protect a clinically significant degree of visual function in a retina that would otherwise become completely dysfunctional and render the patient completely blind. Thus, any of the compositions and methods described herein can be used to rapidly and sustainably restore and protect a clinically significant degree of visual function in the retina of a mammal, such as a human. For example, any of the compositions and methods described herein can provide a clinically significant trophic effect on a diseased retina or provide a regenerative effect on macular and / or dark-adapted visual function.

[0067] The cells in the compositions and populations described herein are populations of closely related cells rather than isolated single cell types.

[0068] These cells are not stem cells per se (as they do not meet the definition of a true stem cell), they are immature and / or plastic, but these cells are unable to generate germ layers (in the absence of further manipulation) and / or are unable to generate all three (3) germ layers (in the absence of further manipulation).

[0069] Furthermore, these cells are pre-configured to form retinal tissue or cells, and therefore, can express progenitor and retinal markers.

[0070] Retinal progenitor cells may appear to be multipotent rather than pluripotent. However, because the cells have never been cultured in a pluripotent state, they are therefore safer. In some embodiments, mammalian fetal retinal cells or RPC cells can be artificially derived from a pluripotent cell line, but they do not contain a population of residual pluripotent cell types, if desired.

[0071] The cells described herein are retinal progenitor cells (RPCs), which can be differentiated from neural precursors and / or neural stem cells (NSCs). Specifically, such mammalian fetal retinal or RPC cells are multipotent but not equivalent to NSCs. For example, mammalian fetal retinal or RPC cells are derived from the retina, not the brain. Furthermore, mammalian fetal retinal or RPC cells generate photoreceptors, whereas brain-derived precursors are poor at generating photoreceptors. Similarly, unlike NSCs, mammalian fetal retinal or RPC cells are multipotent but do not generate oligodendrocytes (in the absence of additional manipulation). For example, mammalian fetal retinal or RPC cells differentiate into retinal cells, including photoreceptors, but do not generate oligodendrocytes.

[0072] The mammalian fetal retinal or RPC cells are derived (or obtainable) from the mammalian fetal neural retina, not from the ciliary margin, ciliary epithelium, or RPE. Furthermore, the mammalian fetal retinal or RPC cells are not derived from differentiated Müller glia, are not postmitotic precursors per se, are not stem cells per se, and / or are not a single isolated cell type per se.

[0073] Mammalian fetal retinal or RPC cells are not found in early embryos (e.g., blastocysts), and furthermore, mammalian fetal retinal or RPC cells are not found in any meaningful abundance in normal adult mammals (e.g., humans).

[0074] Furthermore, retinal progenitor cells do not persist for the life of the organism, but these mammalian fetal retinal cells or RPC cells are found in their natural abundance in the developing (fetal) mammalian (e.g., human) retina.

[0075] Mammalian fetal retinal cells or RPCs are predominantly mitotic when grown under proliferation conditions, although a minority mixture of post-mitotic cells may also be included in any of the compositions and populations described herein.

[0076] Mammalian fetal retinal cells or RPC cells are immunologically tolerated as ocular allografts in unrelated mammals, such as humans. Therefore, RPCs have low immunogenicity when placed in the eye. As a non-limiting example, these mammalian fetal retinal cells or RPC cells can be transplanted into the vitreous cavity or subretinal space for therapeutic and / or preventive therapy of mammalian or human vision or retinal diseases.

[0077] In an alternative embodiment, the mammalian fetal retinal cells or RPC cells do not carry any risk (or are substantially free of) any risk of tumor formation or other unwanted cell growth.

[0078] Mammalian fetal retinal cells or RPC cells can be cultured as spheres or adherent monolayers, or as spheres and then as monolayers, and / or as a combination of spheres and monolayers.However, spheres are not necessary, and in some embodiments, cells are transplanted as dissociated cells rather than as spheres, or as a mixture of dissociated cells and spheres.Mammalian fetal retinal cells or RPC cells contain transplanted cells that can coalesce in the vitreous body and become spheres as needed.

[0079] In an alternative embodiment, retinal progenitor cells and cell populations containing them are not immortal, nor are they immortalized or forced to immortalize. Although cells do not proliferate indefinitely, the exemplary cell culture methods described herein can improve the proliferation rate and duration and / or significantly improve the donor cell yield for a given tissue donation. As used herein, an "immortal" cell line is a cell line that can divide indefinitely, while a "non-immortal" cell line can divide for a limited number of passages. For example, non-immortal retinal progenitor cells can divide for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more passages.

[0080] RPCs may be non-genetically modified cells, or they may be genetically modified (e.g., stably, transiently, or inducibly transformed) using any method(s) known in the art. For example, retinal progenitor cells can be genetically modified to express one or more heterologous or exogenous nucleic acid sequences of interest. The nucleic acid sequence may be "exogenous," meaning that it is foreign to the cell into which the vector is introduced, or that the sequence is homologous to a sequence in the cell but is located in a location within the host cell nucleic acid where it is not normally found. Nucleic acid sequences include, but are not limited to, plasmids, amplicons, cDNAs, mRNAs, antisense RNAs, and siRNAs. The term "gene" refers to a nucleic acid unit that encodes a functional protein, polypeptide, or peptide. As will be understood by those skilled in the art, this functional term includes genomic sequences, cDNA sequences, and smaller engineered gene segments that express or can be adapted to express proteins, polypeptides, domains, peptides, fusion proteins, and mutants.

[0081] Any method known in the art can be used to genetically modify cells. One exemplary method is to insert a gene into the cells of a tissue using a recombinant viral vector. To introduce an exogenous nucleic acid fragment encoding a therapeutic agent into target cells and / or tissues, any one of several different vectors known in the art can be used, such as viral vectors, plasmid vectors, linear DNA, etc. These vectors can be inserted using any of the following methods, as known in the art: infection, transduction, transfection, calcium phosphate-mediated transfection, DEAE-dextran-mediated transfection, electroporation, liposome-mediated transfection, biolistic gene delivery, liposomal gene delivery using fusogenic and anionic liposomes (which are an alternative to the use of cationic liposomes), direct injection, receptor-mediated uptake, magnetoporation, ultrasound, etc.

[0082] As used herein, "vector" refers to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell capable of replicating it. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). Those skilled in the art should be well equipped to construct vectors using standard recombinant techniques as described in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY; Ausubel et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences. In addition to encoding a modified polypeptide, the vector can also encode an unmodified polypeptide sequence, such as a tag or targeting molecule. Useful vectors encoding such fusion proteins include pIN vectors, vectors encoding a stretch of histidine, and pGEX vectors, which can be used to generate glutathione S-transferase (GST)-soluble fusion proteins for subsequent purification and isolation or cleavage.

[0083] Vectors can be designed primarily for introducing heterologous nucleic acid molecules, such as genes, into cells that are "operably linked" to or under the control of one or more regulatory sequences. A "promoter" refers to one or more transcriptional control modules clustered around an initiation site for RNA polymerase II and other transcriptional activator proteins. Any promoter / enhancer combination (according to the Eukaryotic Promoter Database EPDB) can be used to drive expression of the nucleic acid molecule of interest (i.e., constitutive, inducible, repressible, tissue-specific). Furthermore, vectors can contain selectable markers to facilitate their manipulation in vitro or ex vivo. Vectors can also contain polyadenylation signals, which can be obtained from the human growth hormone (hGH) gene, bovine growth hormone (BGH) gene, or SV40. Furthermore, vectors can contain internal ribosome binding site (IRES) elements, which are used to create multigene or polycistronic messages. IRES elements can bypass the ribosome scanning model of 5'-methylated cap-dependent translation and initiate translation at internal sites (Pelletier, J. and Sonenberg, N. (1988) Nature 334(6180): 320-325). IRES elements can link heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. IRES elements make each open reading frame accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter / enhancer to transcribe a single message.

[0084] In some embodiments, vector is a viral vector.Viral vectors known in the art include, but are not limited to, adenovirus vector, retrovirus vector, vaccinia virus vector, adeno-associated virus (AAV) vector, polyomavirus vector, alphavirus vector, rhabdovirus vector, lentivirus vector, Epstein-Barr virus vector, picornavirus vector or herpesvirus vector.In the embodiment where viral vector is AAV vector, any serotype of AAV vector known in the art can be used.For example, AAV vector can be AAV1, AAV2, AAV4, AAV5, AAV8 or AAV9.AAV can be pseudotyped, and the capsid protein and viral genome from different viral serotypes (for example, the inverted terminal repeat from one AAV serotype and the capsid from a different serotype) can be mixed.

[0085] In other embodiments, nucleic acid sequences can be incorporated into liposomes or lipid formulations. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an internal aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of a closed structure, trapping water and dissolved solutes between the lipid bilayers (Ghosh, PC and Bachhawat, BK (1991) Targeted Diagn. Ther. 4: 87-103). One example of a commercially available liposome or lipid formulation is Lipofectamine (Invitrogen). Others include FuGENE (Promega), PromoFectin (PromoKine), Affectene (Qiagen), Polyfect (Qiagen), Superfect (Qiagen), and TransMessenger (Qiagen). Isolation of primary retinal cells

[0086] Provided herein are methods for isolating and culturing fetal retinal cells, such as human primary retinal cells, from a sample and / or using a dissociated suspension of fetal retinal cells. In various embodiments, the suspension of fetal retinal cells does not contain tissue or scaffold. Also provided are methods for isolating and characterizing retinal progenitor cells, and compositions containing such cells that are harvested from donor tissue, grown in culture, and formulated for administration to subjects or patients.

[0087] The methods described herein for isolating primary retinal cells from human samples do not require the use of proteases to digest multiple primary retinal cells, which results in a greater number of viable primary retinal cells compared to methods that use proteases or a combination of mechanical dissociation and protease digestion.

[0088] In one aspect, the present disclosure provides a method for isolating primary retinal cells from a human sample, the method comprising: (a) isolating a retinal sample comprising a plurality of primary retinal cells from the human sample; (b) mechanically dissociating the plurality of primary retinal cells in the retinal sample isolated in step (a), thereby producing a dissociated suspension of cells and cell clusters; and (c) determining the viability, quantity, morphology, or a combination thereof, of the primary retinal cells from the retinal sample. The human sample is isolated from a human donor. The donor may be 17 to about 20 weeks old. In some embodiments, the method for isolating primary retinal cells described herein comprises isolating at least 30×10 6 to generate viable primary retinal cells, which are then cultured to generate retinal progenitor cells.

[0089] In some embodiments, the sample is an eye or a pair of eyes isolated from a mammal, such as a mouse, rat, rabbit, cat, dog, monkey, non-human primate, or human. In some embodiments, the sample is from an agricultural animal, such as a horse, cow, or sheep.

[0090] Samples used to isolate and / or culture cell populations can be obtained from healthy subjects (i.e., individuals without retinal disease) or diseased subjects, and can include fresh as well as frozen retinal cell populations. Sources include, but are not limited to, intact eyes or retinal tissue obtained from embryonic, fetal, pediatric, or adult tissue, or other sources. The methods described herein can include additional enrichment or purification procedures or steps for cell isolation by positive selection for other retinal progenitor cell-specific markers. Retinal progenitor cells and cell populations can be obtained or harvested from any mammalian species or subject, such as humans, primates, horses, cows, pigs, dogs, cats, ferrets, rabbits, rodents, such as mice, rats, and hamsters.

[0091] In some embodiments, the cells are harvested from a mammalian fetal retina at a stage in the subsequent development of the retina, but before the photoreceptor outer segments are fully formed throughout the retina and before retinal vascularization is complete or substantially complete. For human fetuses, the stage is typically between about 12 and about 28 weeks of gestation (e.g., about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 weeks). In some embodiments, the stage may be between 17 and about 20 weeks of gestation. For non-human cells from larger mammals, such as feline or porcine retinal progenitor cells, the stage is typically between about 3 and about 11 weeks of gestation (e.g., about 3, 4, 5, 6, 7, 8, 9, 10, or 11 weeks). See, for example, Anand-Apte, B. and Hollyfield, JG "Developmental Anatomy of the Retinal and Choroidal Vasculature." in The Retina and Its Disorders, Besharse, J. and Bok, D., Academic Press, (2001). However, cells can also be obtained from tissues of postnatal or neonatal mammals.

[0092] In some embodiments, the sample is a human sample. In some embodiments, the human sample is one or a pair of eyes from a human donor. In some embodiments, the human donor is about 12 weeks to about 28 weeks gestational age. In some embodiments, the human donor is about 17 weeks to about 20 weeks gestational age. In some embodiments, using a narrower age range of donors improves the consistency of the final yield of retinal progenitor cells during production.

[0093] In some embodiments, the sample is one or a pair of human fetal eyeballs. In some embodiments, the eyeballs have normal morphology. Normal morphology can be determined by visual inspection of characteristics such as intact globe(s), clear cornea, normal shape, or any combination of these characteristics.

[0094] In some embodiments, human retinal tissue can be shipped on ice and delivered within a transport window. The transport window can include holding the cells at the destination or origin for a period of time, for example, on ice or in a refrigerator at a temperature of about 1-8° C. or about 4° C. In some embodiments, the transport window is about 1-40 hours, about 7-40 hours, about 1-34 hours, about 7-34 hours, about 1-26 hours, about 4-26 hours, about 7-26 hours, about 8-26 hours, about 4-18 hours, about 7-18 hours, or about 8-18 hours. In some embodiments, the transport window is about 1 hour, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, or about 26 hours.As a non-limiting example, the transport window may range from about 1 to about 26 (e.g., 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101 7, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, or 26), for example, about 4.5 to about 21.5 hours (for example, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, or 21.5) or about 7 to about 26 hours (e.g., 7, 7.5, 8, 8.5, 9, 9.5 , 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5 or 26 hours).

[0095] In some embodiments, the sample is placed in mammalian cell culture medium after collection from the donor. Mammalian cell culture media that can be used during sample transport include both basal and complex cell culture media. Non-limiting examples of basal cell culture media used during transport include, but are not limited to, Minimum Essential Medium Eagle, ADC-1, LPM (without bovine serum albumin), F10 (Ham), F12 (Ham), DCCM1, DCCM2, RPMI 1640, BGJ Medium (with or without Fitton-Jackson modification), Basal Medium Eagle (BME - supplemented with Earle's salts base), Dulbecco's Modified Eagle Medium (DMEM - serum-free), Advanced DMEM / F-12, Yamane, IMEM-20, Glasgow Modified Eagle Medium (GMEM), Leibovitz L-15 Medium, McCoy's 5A Medium, Medium M199 (M199E - Earle's salts base (salt base)), among others. Examples of suitable medium include medium M199 (containing M199H-Hank's salts base), medium M199 (containing M199H-Hank's salts base), minimum essential medium Eagle (containing MEM-E-Earl's salts base), minimum essential medium Eagle (containing MEM-H-Hank's salts base), and minimum essential medium Eagle (MEM-NAA without non-essential amino acids), such as medium 199, CMRL 1415, CMRL 1969, CMRL 1066, NCTC 135, MB 75261, MAB 8713, DM 145, Williams' G, Neuman & Tytell, Higuchi, MCDB 301, MCDB 202, MCDB 501, MCDB 401, MCDB 411, MDBC 153, and Ultraculture. In some embodiments, the cell culture medium used for transport comprises RPMI-1640. In some embodiments, the cell culture medium used for transport comprises RPMI-1640 supplemented with L-glutamine. In some embodiments, the cell culture medium used for transport comprises Advanced DMEM / F-12, hi some embodiments, the cell culture medium used for transport comprises complete medium.For example, the cell culture medium used for transport includes basal medium supplemented with one or more of N-2 supplement, B27 xeno-free, B27, StemPro, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), or GlutaMAX I. In some embodiments, the cell culture medium used for transport includes one or more antibiotics. For example, the cell culture medium used for transport includes about 30 to 100 micrograms (μg) per milliliter (mL), or about 0.5 to about 50 μg / mL of gentamicin. In some embodiments, the cell culture medium used for transport includes about 50 μg / mL of gentamicin.

[0096] In some embodiments, the human sample is stored at about 1-8° C. immediately after placement in the transport cell culture medium. In some embodiments, the human sample is stored at about 4° C. immediately after placement in the transport cell culture medium. For example, the human sample is stored on ice immediately after placement in the transport cell culture medium.

[0097] The present disclosure provides methods for isolating a retinal sample comprising a plurality of primary retinal cells from a human sample, for example, a sample comprising one or a pair of eyes from a human donor at about 12 to 28 weeks of gestation.

[0098] Retinal progenitor cells can be purified from other tissue components after or simultaneously with the processing of a tissue sample. For example, progenitor cells can be purified from other cells and tissue components after the tissue sample has been cultured under conditions suitable for cell growth and for a time sufficient to allow the cells to adhere to the culture dish. In certain embodiments, cell purification involves obtaining cells that migrate from the tissue sample during culture and are present in the culture medium or loosely attached to a fibronectin or other substrate or feeder cell layer. These cells can be obtained using routine methods, for example, by removing and centrifuging the culture medium to pellet the cells therein, and washing the remaining cells in the culture dish with a solution such as phosphate-buffered saline (PBS) or Hank's balanced salt solution to detach those cells loosely attached as an adherent cell layer. This washing solution can also be subsequently centrifuged to obtain the cells. Purification of retinal progenitor cells and cell populations can further include separating the cells from certain insoluble tissue components, including residual tissue material such as lipids. Cells can be separated from other tissue components by any means known and available in the art, including, for example, using density gradients, centrifugation, sorting by flow cytometry or magnetic cell sorting (MACS), and filtration or a combination thereof.Specific examples of cell purification methods are known in the art and are described, for example, in U.S. Patent No. 6,777,231.Negative separation methods can also be used to extract one or more specific cell types.

[0099] Tissues can also be processed or "dissociated." For example, tissues such as an eyeball or a pair of eyes can be processed or dissected to isolate the retina, and the retina can be dissociated to produce a plurality of primary retinal cells and cell clusters. These primary retinal cells and cell clusters can then be cultured as described herein to produce a plurality of retinal progenitor cells.

[0100] Thus, the present disclosure provides a method for isolating a retinal sample comprising a plurality of primary retinal cells from a human sample. The human sample may comprise, for example, one or a pair of eyeballs from a human donor at about 12-28 weeks of gestation. In some embodiments, the method includes (i) removing one or a pair of human eyeballs from a transport culture medium; (ii) rinsing the one or a pair of human eyeballs with phosphate-buffered saline (PBS) supplemented with antibiotics at about 1-8°C; (iii) removing the optic nerve and mesenchymal tissue from the one or a pair of human eyeballs; (iv) washing the one or a pair of human eyeballs with PBS supplemented with antibiotics at about 1-8°C; (v) using a needle to puncture the edge of each globe of the one or a pair of human eyeballs; (vi) removing the optic nerve and mesenchymal tissue from the one or a pair of human eyeballs, for example, from a human donor at about 12-28 weeks of gestation. The method includes (i) using microscissors to make a circumferential incision along the edge of one or a pair of human eyeballs; (ii) removing the lens, cornea, and associated vitreous body from one or a pair of human eyeballs; (iii) dissociating the retina(s) from the retinal pigment epithelium (RPE) layer to generate an isolated retina or a pair of isolated retinas; and (ix) placing the isolated retina or a pair of isolated retinas in culture medium or PBS at about 1-8°C, where the culture medium or PBS is supplemented with antibiotics. Rinsing (or washing) the sample at various steps can be repeated one to five times or more. For example, the sample can be rinsed one, two, three, four, or five times. In some embodiments, the retinal sample generated by the methods described herein is free of or substantially free of extraocular cells.

[0101] In some embodiments, retinal samples isolated using the methods described herein are dissociated to produce isolated retinal cells and clusters of retinal cells, which are cultured to produce retinal progenitor cells. In some embodiments, the dissociation of the retinal sample is mechanical. In some embodiments, the dissociation includes (i) transferring the retinal sample to a tube, (ii) mechanically dissociating the retinal sample to produce a plurality of dissociated primary retinal cells, (iii) pelleting the plurality of dissociated primary retinal cells by centrifugation, and (iv) removing the supernatant. Mechanical dissociation can be achieved by any means known in the art, including, but not limited to, trituration with a sterile pipette. In some embodiments, trituration is performed multiple times, for example, 2-50 times, 2-10 times, or 2-8 times, or until the retinal sample is in the form of suitably sized cell clusters. In some embodiments, trituration is performed 4-8 times.

[0102] In some embodiments, dissociation of the retinal sample comprises digestion with a protease. In some embodiments, dissociation of the retinal sample comprises digestion with a protease and mechanical dissociation. In some embodiments, the protease is trypsin. Suitable trypsin compositions are known to those skilled in the art and include, but are not limited to, TrypLE (Thermo Fisher Scientific), TrypLE Select (Invitrogen), and TrypLE Express (Invitrogen). For example, the isolated retina can be pipetted in undiluted TrypLE Express. The activity of proteases, such as trypsin, can be neutralized by adding an excess of protease-free medium to stop the reaction. For example, a 5-fold, 10-fold, 15-fold, or 20-fold excess of culture medium can be added to the mixture containing the dissociated retina.

[0103] To produce a "dissociated suspension" of cells and / or cell clusters, dissociation can be carried out by physical dissociation and / or by exposure to an enzyme preparation that facilitates the release of cells from other tissue components. Examples of such enzymes include, but are not limited to, matrix metalloproteinases, clostripain, papain, trypsin, trypsin-like, pepsin, pepsin-like, neutral protease-type, and collagenase. Suitable proteolytic enzymes are described in U.S. Patent Nos. 5,079,160; 6,589,728; 5,422,261; 5,424,208; and 5,322,790. For example, the enzyme preparation can include trypsin alone or in combination with one or more additional enzymes. Enzymatic dissociation can be performed in conjunction with physical dissociation, for example, by mincing, pipetting, chopping, homogenizing, grinding, freeze-thawing, or osmotic shock, to remove undesired cells or connective tissue and ultimately result in single cell cultures or to include cell clusters that can be defined by size, i.e., "small," "medium," and "large." Cell cluster size is subjective and may vary in the practice of the subject invention disclosed herein. The isolated primary retinal cells described herein include isolated cells and clusters of cells. The isolated cluster of primary retinal cells may be about 2-5000 cells, 2-4000 cells, 2-3000 cells, 2-2000 cells, 2-1000 cells, 2-100 cells, 50-5000 cells, 50-4000 cells, 50-3000 cells, 50-2000 cells, 50-1000 cells, 50-100 cells, 500-5000 cells or 500-1000 cells.

[0104] A composition comprising a plurality of isolated primary retinal cells can be pelleted via centrifugation to concentrate the cells, wash or rinse the cells, or change the cell culture medium. For example, the plurality of dissociated primary retinal cells can be washed with culture medium supplemented with antibiotics or PBS, as needed. The plurality of dissociated primary retinal cells can be pelleted via centrifugation at about 100 x g (centrifugal force) to about 1000 x g, about 100 x g to about 500 x g, or about 140 x g to about 300 x g. In some embodiments, the plurality of dissociated primary retinal cells are pelleted by centrifugation at about 140 x g. In some embodiments, the plurality of dissociated primary retinal cells are pelleted by centrifugation at about 300 x g. Centrifugation can be for about 1 minute to 30 minutes. For example, a composition comprising a plurality of isolated primary retinal cells can be centrifuged for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 minutes. Centrifugation can be at any temperature necessary to maintain cell viability. In some embodiments, the composition comprising the plurality of isolated primary retinal cells is centrifuged at about 0°C to 50°C. In some embodiments, the composition comprising the plurality of isolated primary retinal cells is centrifuged at about 4°C. In some embodiments, the composition comprising the plurality of isolated primary retinal cells is centrifuged at about 18°C ​​to 24°C. In some embodiments, the composition comprising the plurality of isolated primary retinal cells is centrifuged at about 37°C.

[0105] In some embodiments of the methods described herein, the methods include (i) resuspending dissociated, pelleted primary retinal cells in culture medium supplemented with antibiotics at about 1-8°C; (ii) seeding a plurality of dissociated retinal cells into one or more coated cell culture flasks or plates containing culture medium, optionally supplemented with antibiotics; (iii) incubating the plurality of dissociated retinal cells at about 10-50°C, optionally incubation at about 37°C; and (iv) determining the quantity and viability of the primary retinal cells and retinal cell clusters. The flasks or plates can be seeded at any suitable density. For example, the flasks or plates can be seeded with about 1 to about 1,000,000,000 cells. Alternatively, the flasks or plates can be seeded with about 1 to about 1,000,000,000 cells per square centimeter (cm). 2 ) about 10,000 to about 5 × 10 6 As a further alternative, flasks or plates may be seeded with cells. 2 ) approximately 0.50 × 10 6 ~Approx. 2.5×10 6 As a further alternative, flasks or plates may be seeded with cells. 2 ) approximately 0.82 × 10 6 ~Approx. 2.06×10 6 As a further alternative, flasks or plates can be seeded with 1 cm 2 Approximately 0.1 × 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 1 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 2 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 3 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 4 x 10 6 ~Approx. 20×106 cells, 1cm 2 Approximately 5 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 6 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 7 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 8 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 9 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 10 x 10 6 ~Approx. 20×10 6 cells, 1cm 2 Approximately 0.2 × 10 6 ~About 10×10 6 cells, 1cm 2 Approximately 0.2 × 10 6 ~Approx. 5×10 6 cells, 1cm 2 Approximately 0.2 × 10 6 ~Approx. 4×10 6 cells, 1cm 2 Approximately 0.2 × 10 6 ~Approx. 3×10 6 cells, 1cm 2 Approximately 0.2 × 10 6 ~Approx. 2×10 6 cells, 1cm 2 Approximately 0.5 × 10 6 ~About 10×10 6 cells, 1cm 2 Approximately 0.5 × 10 6 ~Approx. 5×10 6 cells, 1cm 2 Approximately 0.5 × 10 6 ~Approx. 4×10 6 cells, 1cm 2 Approximately 0.5 × 10 6 ~Approx. 3×10 6 cells or 1cm 2 Approximately 0.5 × 10 6 ~Approx. 2.5×10 6can be seeded with cells.

[0106] In some embodiments, the methods described herein provide a method for detecting inflammatory bowel disease in a patient with a pulmonary artery disease (PAH) comprising administering 20×10 6 ~Approx. 1×10 9 of viable primary retinal cells, approximately 20 × 10 6 ~Approx. 1×10 8 of viable primary retinal cells, approximately 20 × 10 6 ~Approx. 1×10 7 of viable primary retinal cells, approximately 30 × 10 6 ~Approx. 1×10 9 of viable primary retinal cells, approximately 30 × 10 6 ~Approx. 1×10 8 of viable primary retinal cells, approximately 30 × 10 6 ~Approx. 1×10 7 of viable primary retinal cells, approximately 20 × 10 6 ~Approx. 147×10 6 of viable primary retinal cells, approximately 20 × 10 6 ~About 100×10 6 of viable primary retinal cells, or approximately 73 × 10 6 ~Approx. 147×10 6 In some embodiments, the methods described herein produce at least about 20×10 viable primary retinal cells. 6 In some embodiments, the methods described herein produce at least about 30×10 viable primary retinal cells. 6 In some embodiments, the methods described herein produce at least about 35×10 viable primary retinal cells. 6 In some embodiments, the methods described herein produce at least about 30×10 viable primary retinal cells. 6 In some embodiments, the methods described herein produce at least about 45×10 viable primary retinal cells. 6 In some embodiments, the methods described herein produce at least about 50×10 viable primary retinal cells. 6In some embodiments, the methods described herein produce at least about 20×10 viable primary retinal cells. 6 of viable primary retinal cells, at least approximately 30 x 10 6 of viable primary retinal cells, at least approximately 40 x 10 6 of viable primary retinal cells, at least approximately 50 x 10 6 of viable primary retinal cells, at least approximately 60 × 10 6 of viable primary retinal cells, at least approximately 70 × 10 6 of viable primary retinal cells, at least approximately 80 × 10 6 of viable primary retinal cells, at least approximately 90 × 10 6 of viable primary retinal cells, at least approximately 100 x 10 6 of viable primary retinal cells, at least approximately 120 x 10 6 of viable primary retinal cells, at least approximately 140 × 10 6 of viable primary retinal cells, at least approximately 145 × 10 6 of viable primary retinal cells, at least approximately 147 × 10 6 of viable primary retinal cells, at least approximately 150 x 10 6 of viable primary retinal cells, at least approximately 170 × 10 6 of viable primary retinal cells, at least approximately 190 × 10 6 of viable primary retinal cells, or at least approximately 200 × 10 6 to generate viable primary retinal cells.

[0107] Cell morphology, number and viability Provided herein are methods for determining the viability, quantity, and morphology of primary retinal cells from a retinal sample and retinal progenitor cells generated from the primary retinal cells.

[0108] Cell morphology can be determined by any suitable method of optical microscopy.Suitable optical microscopy methods are known to those skilled in the art, including but not limited to differential interference contrast, Nomarski, Hoffman modulation contrast and its variants, fluorescence microscopy and confocal microscopy.If necessary, histochemical staining for one or more markers of isolated primary retinal cells can be used.

[0109] Cell number and viability can be measured using an NC200 Automated Cell Counter (Chemometec) and agglutination cell counting. Alternatively, or in addition, cell number and viability can be measured using trypan blue or a hemocytometer.

[0110] In some embodiments, the percentage of viable counted cells is between about 10% and about 100%, or between about 68% and about 85%.

[0111] Mammalian fetal retinal or RPC cells express quantitatively distinct gene profiles, for example, as described herein; or they express quantitatively distinct soluble factor profiles; or they express quantitatively distinct surface marker profiles. Furthermore, mammalian fetal retinal or RPC cells have gene profiles that are not fixed, constant, or invariant. Rather, they have gene profiles that change quantitatively dynamically over time in culture.

[0112] The subject invention disclosed herein relates to cell populations containing mammalian retinal progenitor cells isolated by defined cell culture methods and expressing characteristic markers. The cell populations can be cultures of cells isolated from a mammal and grown in vitro. For example, the cultures can include suspensions of cells or adherent cells cultured in culture plates, dishes, flasks, or bioreactors. The samples can be homogeneous or heterogeneous, as determined by the expression of one or more markers defined herein. The cell populations disclosed herein can be mixed cell populations and contain a mixture of undifferentiated and differentiated cells. The relative expression levels of markers characteristic of retinal progenitor cells defined herein can vary among cells within the population.

[0113] Retinal progenitor cells can be characterized by their expression of molecular markers, including cell surface markers and non-surface ("gene") markers. While it is common in the art to refer to cells as "positive" or "negative" for a particular marker, the actual expression level is determined quantitatively. The number of molecules on the cell surface (or elsewhere) can differ by several logs and still be characterized as "positive." Those skilled in the art will also understand that cells that stain negatively, i.e., whose level of binding of a marker-specific reagent is not detectably different from a control, e.g., an isotype-matched control, can express small amounts of the marker. Characterization of the level of labeling ("staining") allows for fine distinction between cell populations. The staining intensity of cells can be monitored by flow cytometry, in which a laser detects the quantitative level of a fluorescent dye (proportional to the amount of cell surface marker bound by a specific reagent, e.g., an antibody). Flow cytometry or FACS can also be used to separate cell populations based on the strength of binding to the specific reagent as well as other parameters such as cell size and light scattering. Although absolute levels of staining may vary depending on the particular fluorochrome and reagent preparation, data can be normalized to a control.

[0114] To normalize the distribution to a control, each cell is recorded as a data point with a specific staining intensity. These data points can be presented on a logarithmic scale, where the unit of measurement is arbitrary staining intensity. As an example, the most brightly stained cells in a sample may be 4 logs more intense than unstained cells. When presented in this manner, cells within the highest log of staining intensity are bright, while those within the lowest intensity are negative. "Low" positive staining cells have a level of staining that exceeds the brightness of an isotype-matched control, but is not as intense as the most brightly staining cells typically found in the population. Low positive staining cells can have unique characteristics that differ from the negative and brightly stained positive cells of a sample. Alternative controls can utilize substrates with a defined density of markers on their surface, such as engineered beads or cell lines that provide a positive control for intensity.

[0115] Marker expression can change during culture of the retinal tissue from which the retinal progenitor cells and cell populations are derived. For example, differences in marker expression can be influenced by culture conditions such as oxygen levels (e.g., atmospheric oxygen conditions, i.e., "normoxic" conditions; or hypoxic conditions, also known as "hypoxic" conditions). By way of non-limiting example, hypoxic conditions can include about 0.5% to 10% oxygen (e.g., about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10%). In some embodiments, hypoxic conditions can include about 0.5% to 5%, about 1% to 5%, or about 1% to 3%. Those skilled in the art will recognize that marker expression in retinal progenitor cells and cell populations is not static but can vary as a function of one or more culture conditions, such as medium, oxygen level, passage number, culture time, etc.

[0116] Retinal progenitor cells and cell populations can express one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, twenty or more, twenty-five or more, thirty or more markers defined herein, or any increment therebetween up to 50 markers. Culturing primary retinal cells and retinal progenitor cells (RPCs)

[0117] Provided herein are methods for culturing primary retinal cells and retinal progenitor cells to generate populations of retinal progenitor cells for transplantation and therapeutic applications.

[0118] The methods described herein can generate a large amount of viable cells.For example, the methods described herein can generate about 1,000,000,000 retinal progenitor cells or more at the time of harvesting.In some embodiments, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the cells are viable.

[0119] In some embodiments, donor cells can be cultured without antibiotics to avoid cell modification. Furthermore, because contamination by subclinical microorganisms can be excluded without antibiotics, very low passage cells can be used. In alternative embodiments, the use of low passage cells has a low risk of transformation and / or tumor formation. Furthermore, the use of low passage cells is closest to the natural cells present in the developing retina.

[0120] In some embodiments, primary retinal cells and retinal progenitor cells are cultured using antibiotics. Suitable antibiotics include, but are not limited to, penicillin, streptomycin, and gentamicin. In some embodiments, the antibiotic comprises gentamicin. In some embodiments, the gentamicin is at a concentration of about 0.5-50 μg / mL, e.g., about 0.5-40 μg / mL, about 5-50 μg / mL, or about 5-35 μg / mL. In some embodiments, the gentamicin is at a concentration of about 50 μg / mL. In some embodiments, the gentamicin is at a concentration of about 30 μg / mL.

[0121] Any suitable basal medium can be used for the growth and cultivation of RPCs. Cell culture describes the process of growing cells under controlled conditions, generally outside their natural environment. Cell populations are grown or cultivated in any cell culture medium known in the art. The term "basal medium" refers to any medium capable of supporting cell growth. The basal medium provides standard inorganic salts such as zinc, iron, magnesium, calcium and potassium, vitamins, glucose, a buffer system, and key amino acids. Basal media that can be used in the present invention include, but are not limited to, Minimum Essential Medium Eagle, ADC-1, LPM (without bovine serum albumin), F10 (Ham), F12 (Ham), DCCM1, DCCM2, RPMI 1640, BGJ medium (with or without Fitton-Jackson modification), Basal Medium Eagle (BME - supplemented with Earle's salt base), Dulbecco's Modified Eagle Medium (DMEM - serum-free), Yamane, IMEM-20, Glasgow Modified Eagle Medium (GMEM), Leibovitz, among others. L-15 medium, McCoy's 5A medium, medium M199 (M199E-containing Earle's salt base), medium M199 (M199H-containing Hank's salt base), minimal essential medium Eagle (MEM-E-containing Earle's salt base), minimal essential medium Eagle (MEM-H-containing Hank's salt base), and minimal essential medium Eagle (MEM-NAA with non-essential amino acids), such as medium 199, CMRL 1415, CMRL 1969, CMRL 1066, NCTC 135, MB 75261, MAB 8713, DM 145, Williams' G, Neuman & Tytell, Higuchi, MCDB 301, MCDB 202, MCDB 501, MCDB 401, MCDB 411, MDBC 153, and Ultraculture. In an alternative embodiment, the media for use in culturing retinal progenitor cells disclosed herein are Advanced DMEM / F12 and Ultraculture. Some of these media are summarized in Methods in Enzymology, Volume LVIII, "Cell Culture," pp. 62-72.

[0122] In some embodiments, the medium comprises Dulbecco's Modified Eagle's Medium DMEM / F12, Advanced DMEM / F12, Knockout DMEM / F12, Neurobasal Medium, ReNcell, or Ultraculture Medium. In some embodiments, the medium comprises DMEM / F12.

[0123] "Conditioned medium" refers to a medium that has been modified compared to a basal or base medium. For example, a medium can be conditioned by adding or subtracting molecules such as nutrients and / or growth factors from the original levels found in the basal medium. A medium can be conditioned by allowing a specific type of cell to grow and be maintained in the medium under specific conditions for a certain period of time. For example, a medium can be conditioned by allowing retinal progenitor cells to expand, differentiate, or be maintained in a medium of a defined composition at a defined temperature for a defined period of time. As one skilled in the art will appreciate, numerous combinations of cells, medium types, durations, and environmental conditions can be used to generate an almost limitless array of conditioned media.

[0124] Examples of cell culture supplements or additives include, but are not limited to, components that partially or completely replace the role of serum in supporting cell survival or growth. For example, supplements can include insulin, transmetalloproteins, trace elements, vitamins, or other factors. These factors are not typically included in basal media but are supplied by the serum typically used in cell culture. Supplements or additives can include at least one or more of the following components that support cell growth: one or more insulins or their substitutes, one or more transmetalloproteins or their substitutes, one or more trace elements (e.g., selenium, iron, zinc, copper, cobalt, chromium, iodine, fluoride, manganese, molybdenum, vanadium, nickel, tin), one or more vitamins (e.g., vitamin C, vitamin E, vitamin A, B vitamins), one or more salts (e.g., sodium salts, magnesium salts, calcium salts, or phosphate salts), one or more buffers (e.g., phosphate-buffered saline, HEPES buffer), one or more amino acids (e.g., L-glutamine), one or more or multiple hormones, hormone-like compounds or growth factors (e.g., transferrin, EGF, NGF, ECGF, PDGF, FGF, IGF, LIF, interleukins, interferons, TGF, and / or VEGF, glucagon, corticosteroids, vasopressin, prostaglandins and other growth factors, etc.), serum albumin or a substitute thereof, one or more carbohydrates (glucose, galactose, fructose, mannose, ribose, glycolytic metabolites), one or more antibiotics and / or antifungals (e.g., penicillin, streptomycin, fungizone), and one or more lipids (e.g., free and protein-bound fatty acids, triglycerides, phospholipids, cholesterol, ethanolamine). Exemplary supplements include N-2 (N2) supplements. Many commercially available serum replacement additives, such as Knockout Serum Replacer (KOSR), N2, B27, StemPro (sometimes referred to herein as Stempro), Insulin-Transferrin-Selenium Supplement (ITS), and G5, are well known and readily available to those of skill in the art.These additives are characterized by clearly defined components, so that the concentrations of the components can be determined based on their proportions in the medium. In some embodiments, the culture medium comprises human epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF).

[0125] As non-limiting examples, cells and / or small cell clusters are cultured in a sterile environment containing serum-free or serum-containing medium and antibiotics and antimycotics, or no antibiotics or antimycotics, for no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 passages. Cells and / or small cell clusters are cultured in a basal culture medium (e.g., Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12™ (DMEM / F12™) medium or Advanced DMEM / F12™ medium (Gibco-Invitrogen-Life Technologies, Carlsbad, Calif.)) or ULTRACULTURE™ medium (BioWhittaker-Lonza Walkersville, Inc., Walkersville, Md.), optionally with N2 supplement (Invitrogen) or B27 or B27 xeno-free (Invitrogen), L-glutamine or GlutaMax or GlutaMAX-I (Invitrogen), and human recombinant growth factors, including, for example, EGF and bFGF (Invitrogen), or other growth factors. For example, DMEM / F12™ medium is used for human cells, and ULTRACULTURE™ medium is used for feline or canine cells.

[0126] In some embodiments, the cells and / or cell clusters are cultured for at least 1, 2, 3, 4, or 5 passages. In some embodiments, the cells and / or cell clusters are cultured for more than 5 passages. In some embodiments, the culture medium comprises Dulbecco's Modified Eagle's Medium (DMEM / F12), Advanced DMEM / F12, Knockout DMEM / F12, Neurobasal Medium, ReNcell, and Ultraculture Medium. In some embodiments, the culture medium comprises Advanced DMEM / F12.

[0127] In some embodiments, the culture medium comprises Advanced DMEM / F12, N-2 supplement, GlutaMAX I, recombinant human epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF). In some embodiments, the culture medium further comprises B27, B27 xeno-free, or StemPro. In some embodiments, the culture medium comprises gentamicin at a concentration of about 30 μg / mL.

[0128] The culture medium can also be supplemented with albumin, or human, feline, or canine albumin, or recombinant albumin, if desired. As a non-limiting example, albumin can be added in an amount to have an initial concentration of about 1.0 mg / ml.

[0129] Mammalian retinal progenitor cell cultures can be produced in reduced-serum or serum-free media. Examples of serum include fetal bovine serum, calf serum, newborn calf serum, goat serum, horse serum, human serum, rabbit serum, rat serum, and mouse serum, among others. Under certain culture conditions, serum concentrations range from about 0.05% v / v to about 20% v / v (e.g., 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 1, 1.5, 2, 2.0). 5, 3, 3.5, 5, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5 or 20%). For example, in some differentiation processes, the serum concentration in the medium is less than about 0.05% (v / v), less than about 0.1% (v / v), less than about 0.2% (v / v), less than about 0.3% (v / v), less than about 0.4% (v / v), less than about 0.5% (v / v), less than about 0.6% (v / v), less than about 0.7% (v / v), less than about 0.8% (v / v), less than about 0.9% (v / v), The percentage of retinal progenitor cells in the culture medium may be less than about 1% (v / v), less than about 1% (v / v), less than about 2% (v / v), less than about 3% (v / v), less than about 4% (v / v), less than about 5% (v / v), less than about 6% (v / v), less than about 7% (v / v), less than about 8% (v / v), less than about 9% (v / v), less than about 10% (v / v), less than about 15% (v / v), or less than about 20% (v / v). In some embodiments, retinal progenitor cells and cell populations comprising retinal progenitor cells are grown without serum (“serum-free”), without serum substitutes, and / or without any supplements.

[0130] Retinal progenitor cells or cell populations containing retinal progenitor cells are cultured under "xeno-free" conditions. "Xeno-free" or "xenogen-free" refers to conditions in which cells of a particular species (e.g., human cells) are grown or cultured in the presence of human products or supplements (e.g., human serum albumin, human serum) but not in the absence of products from other species. This is particularly important for cells used for human transplantation. Cells exposed to various undefined animal-derived products make them undesirable for clinical applications due to increased risk of transplant rejection, immune responses, and viral or bacterial infections, prions, and unidentified zoonotic diseases. Furthermore, for use in all mammals, including humans or non-human mammals (e.g., veterinary use), cells are screened for normal karyotype or the presence of infection or contamination, such as mycoplasma, gram-negative bacteria (e.g., endotoxin testing), fungi, etc. Cells can also be screened for transformation to a tumorigenic or cancerous phenotype by telomerase activity assays, hTERT gene expression and growth in soft agar, or tumor formation in nude mice. Such assays are known in the art and well within the purview of one of ordinary skill in the art.

[0131] Retinal progenitor cells or cell populations containing retinal progenitor cells can be cultured on a feeder cell layer (e.g., embryonic or adult fibroblasts) or in the presence of an extracellular matrix scaffold or substrate, such as collagen, entactin, heparin sulfate proteoglycan, fibronectin, laminin, gelatin, or Matrigel. For example, PURECOL® collagen is known as the standard for whole collagen for purity (>99.9% collagen content), functionality, and the most native-like collagen available. PURECOL® collagen is approximately 97% type I collagen, with the remainder consisting of type III collagen, making it ideal for coating surfaces and for use as a thin layer or solid gel for culturing cells. Another example of a scaffold or substrate known in the art is CELLstart (Invitrogen).

[0132] In some embodiments, cell culture conditions can include growing cells in an incubator set at 37° C. and 5% CO. Primary retinal cells, retinal progenitor cells, or cell populations containing same can be cultured under normoxic or atmospheric conditions (about 20% O), or can be grown under conditions that approximate the oxygen levels of the developing fetal retina during pregnancy, i.e., "low" or "hypoxic" conditions, such as 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% oxygen, or any increment therebetween. In some embodiments, cell culture conditions can include growing cells in an incubator set to: (1) 37°C with 0-30% CO2 and 0-50% O2; (2) 37°C, 5% or less CO2 and 20% or less O2; or (3) 37°C, 5% or less CO2 and 3% or less O2.

[0133] Plating density refers to the number of cells per volume of culture medium or per cm2 in adherent culture. A related term is "confluency," which is commonly used as a measure of the number of cells in a cell culture dish or flask and refers to the coverage of the dish or flask by the cells. For example, 100 percent confluency means that the dish is completely covered by cells, leaving no more room for cells to grow, while 50 percent confluency means that roughly half of the dish is covered, leaving room for cells to grow.

[0134] In some embodiments, the method includes a first passage, wherein the first passage is performed by dividing the culture flask or plate into 1 square centimeter (cm 2 ) approximately 0.5 × 10 6 ~Approx. 3.0×10 6 cells, approximately 0.5 x 10 6 ~Approx. 5.0×10 6 cells / cm 2 , about 0.55×10 6 ~Approx. 4.0×10 6 cells / cm 2 , about 0.55×10 6 ~Approx. 3.0×10 6 cells / cm 2 , about 0.55×10 6 ~Approx. 2.5×10 6 cells / cm 2 , or approximately 0.55 × 10 6 ~Approx. 2.1×10 6 cells / cm 2 In some embodiments, the first passage involves seeding the culture flask or plate with cells at a density of about 0.5 x 10 6 ~Approx. 3.0×10 6 cells / cm 2 In some embodiments, the first passage involves seeding the culture flask or plate with cells at a density of about 0.59 x 10 6 ~Approx. 2.29×10 6 cells / cm 2 This involves seeding the cells at a density of 1000×1000×1000.

[0135] In some embodiments, the method includes a second passage, wherein the second passage comprises culturing the culture flask or plate to about 0.05 x 10 6 ~Approx. 1×10 6 cells / cm 2 , about 0.07×10 6 ~Approx. 0.80×10 6 cells / cm 2 , about 0.10×10 6 ~about 0.5×10 6 cells / cm 2 , about 0.10×10 6 ~about 0.4×10 6 cells / cm 2 , about 0.13×10 6 ~Approx. 0.35×10 6 cells / cm 2 , or approximately 0.14 × 10 6 ~Approx. 0.32×10 6 cells / cm 2 In some embodiments, the second passage involves seeding the culture flask or plate with cells at a density of about 0.1 x 10 6 ~about 0.5×10 6 cells / cm 2 In some embodiments, the second passage involves seeding the culture flask or plate with cells at a density of about 0.14 x 10 6 ~Approx. 0.43×10 6 cells / cm 2 This involves seeding the cells at a density of 1000×1000×1000.

[0136] In some embodiments, the method includes a third passage, wherein the third passage comprises culturing the culture flask or plate to about 0.01 x 10 6 ~about 0.5×10 6 cells / cm 2 , about 0.02×10 6 ~about 0.45×10 6 cells / cm 2 , about 0.03×10 6 ~Approx. 0.40×10 6 cells / cm 2 , about 0.04×10 6 ~Approx. 0.30×10 6 cells / cm 2 , about 0.05×10 6~Approx. 0.20×10 6 cells / cm 2 or approximately 0.05 x 10 6 ~about 0.10×10 6 cells / cm 2 In some embodiments, the third passage involves seeding the culture flask or plate with cells at a density of about 0.03 x 10 6 ~Approx. 0.2×10 6 cells / cm 2 In some embodiments, the third passage involves seeding the culture flask or plate with cells at a density of about 0.05 x 10 6 ~about 0.1×10 6 cells / cm 2 This involves seeding the cells at a density of 1000×1000×1000.

[0137] In some embodiments, the method includes a fourth, and optionally further, passage, wherein the fourth and further passages increase the culture flask or plate to between about 10,000 and about 60,000 cells / cm. 2 , about 10,000 to about 50,000 cells / cm 2 , about 10,000 to about 40,000 cells / cm 2 , about 20,000~60,000 cells / cm 2 , about 20,000~50,000 cells / cm 2 or about 20,000 to about 40,000 cells / cm 2 In some embodiments, the fourth passage involves seeding the culture flask or plate with cells at a density of about 10,000 to about 60,000 cells / cm. 2 In some embodiments, the fourth passage involves seeding the culture flask or plate with cells at a density of about 20,000 to about 40,000 cells / cm. 2 This involves seeding the cells at a density of 1000×1000×1000.

[0138] In some embodiments, the method involves seeding a culture flask with cells at a higher density in earlier passages and at a lower density in later passages. Without wishing to be bound by theory, during the first few passages, cells are converted from cell clusters to single cells, and this gradual conversion from clusters to cells is believed to contribute to the increased cell viability of the method described herein. Later passages are seeded as single cells, and the seeding density quickly decreases and then becomes consistent. As a non-limiting example, cells are seeded in a culture flask or plate at about 0.5 x 10 in the first passage. 6 ~Approx. 3.0×10 6 cells / cm 2 , and approximately 0.1 × 10 at the second passage. 6 ~about 0.5×10 6 cells / cm 2 , and approximately 0.03 × 10 at the third passage. 6 ~Approx. 0.2×10 6 cells / cm 2 , and about 10,000 to about 60,000 cells / cm at the fourth and further passages. 2 As a further non-limiting example, cells may be seeded in a culture flask or plate at a density of about 0.59 x 10 cells at the first passage. 6 ~Approx. 2.29×10 6 cells / cm 2 , and approximately 0.14 × 10 at the second passage. 6 ~Approx. 0.32×10 6 cells / cm 2 , and approximately 0.05 × 10 at the third passage. 6 ~about 0.1×10 6 cells / cm 2 , and about 20,000 to about 40,000 cells / cm at the fourth and further passages. 2 The seeds are sown at a density of

[0139] In some embodiments, the period between direct successive passagings is 2-8 days, 3-6 days, 4-5 days, or 3-4 days. In some embodiments, the period between passagings is 4 days. In some embodiments, the period between direct successive passagings is 3 days.

[0140] In some embodiments, the passaging protocol includes target thresholds for the number of viable cells, and the cell culture is terminated if these target thresholds are not met. For example, the cell culture can be terminated at the end of the third passage (P3) if less than 90,000,000, 100,000, 110,000,000, 120,000,000, 130,000,000, 140,000,000, or 150,000,000 viable cells are generated. By way of further example, the cell culture can be terminated at the end of passage 4 (P4) when fewer than 200,000,000, fewer than 250,000,000, fewer than 300,000,000, fewer than 350,000,000, fewer than 400,000,000, fewer than 450,000,000 or fewer than 500,000,000 viable cells are generated.

[0141] Passaging (also known as subculturing or splitting cells) involves transferring a small number of cells to a new container. Cells can be cultured for longer periods if they are split regularly, because this avoids the senescence associated with prolonged high cell densities. Suspension cultures are easily passaged in small cultures containing a few cells diluted with a larger volume of fresh medium. For adherent cultures, cells must first be detached. This is commonly performed with an enzyme mixture such as trypsin-EDTA or a trypsin equivalent and EDTA, or a non-enzyme solution such as cell dissociation buffer; however, various enzyme or non-enzyme mixes or preparations are available for this purpose. A small number of detached cells can then be used to seed a new culture.

[0142] In some embodiments, cells are treated with different trypsin or equivalent-containing solutions at the first, second, and third passages. In an exemplary protocol, cells are treated with a first enzyme solution containing TrypLE and ethylenediaminetetraacetic acid (EDTA) in a 1:4 ratio at the first passage, a second enzyme solution containing TrypLE, EDTA, and Dulbecco's phosphate-buffered saline (DPBS) in a 1:1:3 ratio at the second passage, and a third enzyme solution containing TrypLE and DPBS in a 1:1 ratio at the third and all subsequent passages. In a further exemplary protocol, cells are treated with a first enzyme solution containing TrypLE, EDTA, and PBS in a 1:1:3 ratio at the first passage, a second enzyme solution containing TrypLE and DPBS in a 1:1 ratio at the second passage, and a third enzyme solution containing TrypLE and DPBS in a 1:1 ratio at the third and all subsequent passages. Cells can be treated with trypsin or an equivalent solution for approximately 5-20 minutes, approximately 6-10 minutes, approximately 5-10 minutes, approximately 7-8 minutes, or approximately 5-7 minutes. Cell viability, number, and / or morphology can be determined at any passage. For example, cell viability and number can be determined at the third and fourth passages to determine whether to terminate the cell culture or to determine cell seeding density. Most primary cell cultures have a limited lifespan and do not proliferate indefinitely. After a certain number of population doublings (called the Hayflick limit), cells undergo a senescence process, generally ceasing to divide while retaining viability. In some embodiments, retinal progenitor cells and cell populations can be cultured for, e.g., 10 passages or less, and passaged for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 passages. In some embodiments, RPCs are passaged about 4-6 (e.g., 4, 5, or 6) times under standard oxygen conditions, and optionally subsequently cultured for about 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) passages under reduced oxygen conditions.

[0143] In alternative embodiments, the cells can be passaged (under normal oxygen conditions, under reduced oxygen conditions, and / or any combination thereof) more than 5 times, e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more passages. In certain embodiments, retinal progenitor cells and cell populations are cultured for about 5 to 32 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32) passages. One of skill in the art will recognize that other methods known in the art can be used to culture cells for more than 32 passages (i.e., 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more passages).

[0144] Any suitable container, such as a flask, plate, or cell stack, can be used to passage cells using the methods described herein. Exemplary flasks include T25 and T75 flasks. CellStacks (CS) are stacked culture chambers available, for example, from Corning. In some embodiments, the flask, plate, or cell stack can be coated. The flask, plate, and cell stack can be coated with fibronectin, ornithine, polylysine, or laminin diluted in Dulbecco's phosphate-buffered saline (DPBS). In some embodiments, the flask, plate, or cell stack is coated with fibronectin. In some embodiments, the fibronectin is xeno-free. If necessary, the flask, plate, or cell stack can be rinsed with medium before placing cells therein.

[0145] In various embodiments, cell sample is screened for the presence of pathogens, bacteria, endotoxins, fungi, mycoplasma, viruses, hepatitis viruses or HIV viruses.Cell sample can also be screened for the presence of normal karyotype; viability; and / or tumorigenicity.Optionally, cell sample does not show elevated telomerase activity.

[0146] In any of these methods, retinal cells and / or retinal tissues can be frozen before or after isolation, selection, and / or culture. Freezing of cells can be achieved using any cryopreservation agent and / or technique commonly used in the art. Frozen cells can be thawed before use using any protocol known in the art.

[0147] The viability of the cells can be tested prior to their use in any of the methods described herein. In alternative embodiments, by way of non-limiting example, at least 70% (e.g., 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) of the cells are viable prior to cryopreservation. In alternative embodiments, after thawing, at least 70% (e.g., 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) of the cells are viable. Similarly, upon cell culture harvest, in alternative embodiments, at least 70% (e.g., 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) of the cells are viable. Determining the number of viable cells at any stage is within the routine level of one skilled in the art.

[0148] Thus, the present disclosure provides a method for cryopreserving multiple retinal progenitor cells generated using the isolation and culture methods described herein. In some embodiments, the method includes (i) enzymatically dissociating the cells using trypsin or an equivalent, (ii) stopping the dissociation with an excess of culture medium or Advanced DMEM / F12, (iii) centrifuging the cells at 10 x g to 10,000 x g for 1 to 30 minutes, (iv) resuspending the cells in culture medium and determining total cell number and viability, (v) adding cryopreservation medium to achieve a final dimethyl sulfoxide (DMSO) concentration of 5 to 30%, (vi) aliquoting multiple cells into individual cryovials, (vii) freezing each vial using a controlled-rate freezer, and (viii) placing each vial of cells in liquid N2. Any suitable freezing method known in the art can be used. For example, cells can be frozen using a Cryo 1C freezing container placed in a -80°C freezer. In some embodiments, the trypsin equivalent is TrypLE, e.g., TrypLE Express or TrypLE Select (e.g., ThermoFisher or Invitrogen). In some embodiments, the cryopreservation medium comprises culture medium and 20% DMSO. In some embodiments, the cryopreservation medium is added to the cells and cell culture medium in a 1:1 ratio to achieve a final concentration of 10% DMSO. In some embodiments, the plurality of retinal progenitor cells is about 0.5 x 10 per cryovial. 6 ~50×10 6 In some embodiments, multiple retinal progenitor cells are collected at approximately 0.5 x 10 per mL of culture medium (e.g., culture medium plus 10% DMSO). 6 ~About 40×10 6 Cells, approximately 0.5 x 10 per mL of medium 6 ~Approx. 20×10 6 Cells, approximately 0.5 x 10 per mL of medium 6 ~About 10×10 6 Cells, approximately 1 x 10 per mL of medium 6 ~About 40×10 6 Cells, approximately 1 x 10 per mL of medium 6~About 20×10 6 Cells, approximately 1 x 10 per mL of medium 6 ~About 10×10 6 Cells, approximately 10 x 10 per mL of medium 6 ~Approx. 30×10 6 Cells, approximately 10 x 10 per mL of medium 6 ~About 20×10 6 Cells, approximately 2 x 10 per mL of medium 6 ~About 10×10 6 Cells, approximately 2 x 10 per mL of medium 6 ~Approx. 8×10 6 cells, or approximately 2 x 10 per mL of medium 6 ~Approx. 5×10 6 In some embodiments, a plurality of retinal progenitor cells is obtained at approximately 0.5 x 10 per mL of culture medium. 6 ~About 20×10 6 In some embodiments, multiple retinal progenitor cells are obtained at approximately 2 x 10 per mL of culture medium. 6 ~Approx. 8×10 6 In some embodiments, a plurality of retinal progenitor cells is obtained at approximately 10 x 10 per mL of culture medium. 6 The cells are aliquoted and frozen. In some embodiments, the cryovial contains about 1 mL, about 2 mL, about 3 mL, about 4 mL, about 5 mL, about 6 mL, about 7 mL, about 8 mL, about 9 mL, or about 10 mL of cryopreservation medium (e.g., culture medium plus DMSO) and retinal progenitor cells. In some embodiments, the cryovial contains about 1 mL of medium and retinal progenitor cells. In some embodiments, the cryovial contains about 5 mL of medium and retinal progenitor cells.

[0149] In certain embodiments, when kept on ice (e.g., at 0-4°C), the final formulation has been shown to maintain optimal viability (e.g., at least 85%) for up to 4 hours or longer (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours or longer), which in turn allows for localized delivery of the cell preparation to the local clinical site.

[0150] Further expansion of cells under low oxygen conditions can be used to greatly enhance cell yield per donation. For example, in some embodiments, cells can be passaged a total of 5-12 times (i.e., 5, 6, 7, 8, 9, 10, 11, or 12 times) or more. As a non-limiting example, in one embodiment, this can include 4-6 passages (i.e., 4, 5, or 6) in standard oxygen conditions followed by 3-6 passages (i.e., 3, 4, 5, or 6) of secondary hypoxic expansion. However, one of skill in the art will recognize that the total number of passages can be from about 1 to 32 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or more) passages, and that this can include secondary hypoxic expansion of from 1 to 20 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more) passages. Determining the appropriate number of total passages, as well as the number of hypoxic passages, is within the routine level of one of skill in the art. The use of this secondary hypoxic culture passaging greatly increases the yield from working banks of hRPCs (e.g., those derived from culture under normoxic conditions). For example, cells from a standard normoxic bank can be thawed and expanded under hypoxic conditions for an additional 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) passages.

[0151] Fewer hypoxic cell passages can be used, but the resulting yield will likely be lower. Additionally, more hypoxic cell passages can be used, but this potentially carries an increased risk of resulting in an incomplete product with loss of efficacy and / or accumulation of undesirable genetic abnormalities due to potential phenotypic drift.

[0152] After the second hypoxic culture passaging, in some embodiments, the retinal progenitor cells undergo a "recovery period" during which they are allowed to grow under standard oxygen conditions for a short period of time ranging from 1 hour up to 5 days (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 24, 36, 48, 60, 72, 84, 96, 108, or 120 hours). In alternative embodiments, during this recovery period, the cells are allowed to grow without undergoing any further passaging.

[0153] Thus, in one non-limiting example, retinal progenitor cells for use in any of the compositions and methods described herein can be generated using a "hybrid" approach involving (a) culturing for several passages under standard oxygen conditions, followed by (b) culturing for several passages under hypoxic conditions, optionally followed by (c) culturing for a set period under standard oxygen conditions without further passages. Determining the appropriate number of passages under standard oxygen and / or hypoxic conditions, as well as the appropriate duration of the recovery period, is within the routine level of one of ordinary skill in the art.

[0154] The resulting cell products produced using this new culture method were tested in vitro and in animals, and similar results were observed as with cell products that did not undergo secondary hypoxic culture.

[0155] Those skilled in the art will recognize that the addition of this secondary hypoxic component to the overall process lends itself to automated manufacturing methods in that complex procedures such as initial dissection and plating are not required and the passaging performed is entirely standardized for robustly growing cells.

[0156] Further RPCs can be generated by induced pluripotent stem cell (iPS) conversion of existing RPCs and subsequent expansion in a more primitive proliferative state. The iPS can then be redifferentiated back into RPCs using any method(s) known in the art. In this scenario, epigenetic imprinting prior to their acquisition as RPCs aids in reconverting the cells back to their original state, thereby increasing RPC yield and / or promoting the safety of high-yield allogeneic products (i.e., by avoiding contamination with pluripotent cells). This expansion method could provide a very large and potentially limitless (non-senescent) source of RPCs derived from clinically proven RPC samples, without the need for repeated fetal tissue procurement.

[0157] Whether or not such lines are derived from RPCs as described above, RPCs can be further produced from pluripotent cell lines. Such derivation may include partial differentiation into "embryoid bodies" containing primitive retinal structures, i.e., optic cup derivatives, from which RPCs can be harvested, purified, and further expanded.

[0158] A similar method using autologous cells can be performed in which donor cells for iPS cells are obtained from the ciliary epithelium or iris, because both of these tissues are readily available to surgeons and have developmental imprints that overlap (although not exactly the same) with the retina.

[0159] Compositions and Formulations The retinal progenitor cells and cell populations described herein can be formulated as compositions for administration by any or a variety of means, including orally, parenterally, by inhalation spray, nasally, topically, intrathecally, intrathecally, intracerebrally, epidurally, intracranially, or rectally. The compositions and formulations disclosed herein may contain pharmaceutically or veterinarily acceptable liquids, carriers, adjuvants, and vehicles, and may be in the form of liquids, tablets, capsules, implants, aerosols, gels, liposomes, nanoparticles, and the like.

[0160] Retinal progenitor cells and cell populations can be administered to subjects in the form of pharmaceutical or veterinary compositions. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not cause adverse, allergic, or other untoward reactions when administered to animals or humans. As used herein, "pharmaceutically acceptable carriers" include all aqueous and non-aqueous carriers, including water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.

[0161] The pharmaceutically acceptable carrier may optionally include albumin (eg, human albumin), a protein that can enhance cell survival within the preparation.

[0162] Similarly, any of the compositions or preparations disclosed herein may also include the excipient HypoThermosol®-FRS (HTS-FRS) (BioLife Solutions, Inc.), a commercially available cryogenic storage solution / formulation designed to modulate the level of post-storage necrosis and apoptosis in cells stored at low temperatures (2°C to 10°C) for extended periods of time (see, e.g., U.S. Pat. No. 6,921,633; U.S. Pat. No. 6,632,666; and WO2005 / 009766).

[0163] The addition of albumin and / or HTS can be used to extend the survival time of retinal progenitor cells in any of the preparations disclosed herein by up to about 24 hours (i.e., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours).

[0164] Proper fluidity can be maintained, for example, by using coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by using surfactants. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the presence of microorganisms can be ensured both by sterilization procedures and by including various antibacterial and antifungal agents, for example, parabens, chlorobutanol, sorbic acid, etc. It may also be desirable to include isotonic agents, such as sugars and sodium chloride, in the composition. Furthermore, the inclusion of agents that delay absorption, such as aluminum monostearate and gelatin, can result in sustained absorption of the injectable pharmaceutical form. It must be stable under the conditions of manufacture and storage and must be protected from the contaminating action of microorganisms, such as bacteria and fungi. The use of such media and agents for pharmaceutically active substances is well known in the art.

[0165] The retinal progenitor cells or cell populations must be administered to a subject in an effective amount. An "effective amount" or "therapeutically effective amount" refers to the amount of the composition that produces the desired effect. The effective amount depends in part on, for example, the molecule or drug being delivered (in this invention, the retinal progenitor cells or cell populations), the indication for which the therapeutic agent is used, the route of administration, and the size (weight, body surface, or organ size) and condition (age and overall health) of the subject or patient. Thus, a clinician or physician can titrate the dosage and modify the route of administration to achieve optimal therapeutic effect. The effective amount of a particular drug for a particular purpose can be determined using methods well known to those skilled in the art. For any composition defined herein, the effective amount can be initially estimated either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, pigs, or monkeys. Animal models can also be used to determine reasonable concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration to humans.

[0166] Examples of effective amounts of the compositions described herein include volumes of 5 μl, 10 μl, 15 μl, 20 μl, 25 μl, 50 μl, 100 μl, 150 μl, 200 μl, 250 μl, 300 μl, 350 μl, 400 μl, 450 μl, 500 μl, or any increment up to 5000 μl (5 ml) (e.g., 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 22 00, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, ​​3000, 3050, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 37 Examples of suitable cell suspensions include: 100, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, or 5000 μl).

[0167] The upper and lower limits of the volume are limited by the delivery system and / or method. See, for example, Kayikcuiglu, OR et al, (2006) Retina 26 (9): 1089-90. For example, the upper limit of the volume when administered without vitrectomy is approximately 200 μl due to increased intraocular pressure. The upper limit of the volume when administered into the vitreous cavity after vitrectomy is limited by the volume of the vitreous cavity, which may contain up to 5 ml or more. The upper limit of the subretinal injection may be up to 200 μl due to retinal detachment. In alternative embodiments, these volumes may be any of 1000-10,000,000 cells per dose, or 1000-2000 cells per dose, 2000-3000 cells per dose, 3000-4000 cells per dose, 400-5000 cells per dose, 5000-6000 cells per dose, 6000-7000 cells per dose, 7000-8000 cells per dose, 800-9000 cells per dose, 9000-10000 cells per dose, 1000-12000 cells per dose, 13000-14000 cells per dose, 14000-15000 cells per dose, 15000-16000 cells per dose, 16000-17000 cells per dose, 17000-18000 cells per dose, 18000-2000 cells per dose, 19000-21000 cells per dose, 2000-2200 cells per dose, 21000-2300 cells per dose, 22000-2400 cells per dose, 23000-2500 cells per dose, 24000-26000 cells per dose, 25000-3000 cells per dose, 26000-3000 cells per dose, 27000-3000 cells per dose, 28000-3000 cells per dose, 29000-3100 cells per dose, 30000-3200 cells per dose, 31000-3300 cells per dose, 32000-3400 cells per dose, 33000-3500 cells per dose, 34000-3500 cells per dose, 350 0-9000 cells, 9000-10,000 cells per dose, 10,000-15,000 cells per dose, 15,000-20,000 cells per dose, 20,000-25,000 cells per dose, 25,000-30,000 cells per dose, 30,000-35,000 cells per dose, 35,000-40,000 cells per dose, 40,000-45,000 cells per dose 45,000-50,000 cells per dose, 50,000-55,000 cells per dose, 55,000-60,000 cells per dose, 60,000-65,000 cells per dose, 65,000-70,000 cells per dose, 70,000-75,000 cells per dose, 75,000-80,000 cells per dose, 80,000-85,000 cells per dose, 85,000-90,000 cells per dose 00 cells, 90,000-95,000 cells per dose, 95,000-100,000 cells per dose, 100,000-125,000 cells per dose, 125,000-150,000 cells per dose, 150,000-200,000 cells per dose, 200,000-250,000 cells per dose, 250,000-300,000 cells per dose, 300,000-350,000 cells per dose000 cells, 350,000-400,000 cells per dose, 400,000-450,000 cells per dose, 450,000-500,000 cells per dose, 500,000-550,000 cells per dose, 550,000-600,000 cells per dose, 600,000-650,000 cells per dose, 650,000-700,000 cells per dose, 7 Examples of dosages include 00,000-750,000 cells per dose, 750,000-800,000 cells per dose, 800,000-850,000 cells per dose, 850,000-900,000 cells per dose, 900,000-950,000 cells per dose, 950,000-1,000,000 cells per dose, or any increment of 1,000-10,000,000 cells per dose. Dosages may, of course, vary according to the frequency and duration of administration. In alternative embodiments, the dosage of cells in the compositions described herein comprises a large number of cells in a small volume, e.g., 500,000 cells per 100 μl. Cell counts can be counted by any method known in the art, e.g., hemocytometer, spectrometry, Coulter counter, flow cytometry, etc. Administration can be administered once or over the course of several treatments. ,

[0168] The compositions can be delivered, for example, via transcleral delivery as described in U.S. Pat. No. 7,585,517; via a sustained release delivery device for delivery to the interior of a patient's eye as described in U.S. Pat. No. 7,883,717; via a device for insertion into the vitreous region of the eye as described in U.S. Pat. Nos. 5,378,475 or 5,466,233; or via a subcutaneous syringe or oblique insertion channel as described, for example, in U.S. Patent Application Publication Nos. 20110112470 or 20100256597, which describe microneedles for targeted administration to a patient's eye. The cells may also be formulated for parenteral administration to the eye (particularly the vitreous or subretinal space), the vitreous or subretinal space, the retina, the brain, nerves, or the CNS, by transscleral delivery, including via a transvenous route; or via a hydrophilic polymer hydrogel sized to pass through the punctum, as described, for example, in U.S. Patent Application Publication No. 20100209478; or by any method or protocol known in the art, including a device providing access to the subretinal space in the human eye, as described, for example, in U.S. Patent Application Publication No. 20100191176. An anterior chamber paracentesis may also be performed as determined by one of skill in the art. The method, particularly for intravitreal placement, does not require suturing of the sphere during and / or after the procedure. However, for methods utilizing a vitrectomy procedure, suturing of the sphere may be necessary, for example, if the cells are placed in the subretinal space.

[0169] The compositions disclosed herein can also be formulated for intrathecal, intracranial, epidural, subcutaneous, intravenous, intramuscular, and / or intraarterial administration by injection routes, including various infusion techniques, as described, for example, in U.S. Patent Application Publication No. 200500480021. Administration can be accomplished using a catheter or pump, e.g., an intrathecal pump, or an implantable medical device. In alternative embodiments, the methods are described in U.S. Patent Nos. 7,388,042; 7,381,418; 7,379,765; 7,361,332; 7,351,423; 6,886,568; 5,270,192; and U.S. Patent Application Publication Nos. 20040127987; 20080119909; 2008011854 ... This may also involve the administration or transplantation of implants and artificial organs, bioreactor systems, cell culture systems, plates, dishes, tubes, bottles, flasks, and the like, containing the retinal progenitor cells, cell populations, or compositions disclosed herein, such as those described in US Pat. Nos. 080020015; 20070254005; 20070059335; and 20060128015.

[0170] The composition containing retinal progenitor cells or cell populations can be co-administered with one or more drugs, if necessary. Non-limiting examples of drugs include anti-angiogenic agents, such as angiostatin, anecortave acetate, thrombospondin, VEGF receptor tyrosine kinase inhibitors and anti-vascular endothelial growth factor (anti-VEGF) drugs, such as ranibizumab and bevacizumab, pegaptanib, sunitinib and sorafenib, and any of a variety of known small molecules and transcription inhibitors with anti-angiogenic effects; for example, acebutolol, atenolol, bisoprolol, carvedilol, esmolol (asmo known classes of ophthalmic drugs, including glaucoma medications such as adrenergic antagonists, including beta-blockers such as benzodiazepines, labetalol, nadolol, penbutolol, pindolol, propranolol, metipranolol, betaxolol, carteolol, levobetaxolol, levobunolol, and timolol; adrenergic agonists or sympathomimetics, e.g., epinephrine, dipivefrin, clonidine, aparclonidine, and bromide; Limonidine; parasympathomimetics or cholinergic agonists, such as pilocarpine, carbachol, phosphoric acid, and physostigmine, salicylic acid, acetylcholine chloride, eserine, diisopropylfluorophosphate, demecarium bromide; muscarinic agonists; topical and / or systemic agents, such as acetazolamide, brinzolamide, dorzolamide, and methazolamide, ethoxzolamide, diamox, and diclofenamide (di carbonic anhydrase inhibitors, including chlorphenamide; mydriatic / cycloplegic agents, such as atropine, cyclopentolate, succinylcholine, homatropine, phenylephrine, scopolamine, and tropicamide; prostaglandins, such as prostaglandin F2 alpha, antiprostaglandins, prostaglandin precursors, or prostaglandin mimetics, such as bimatoprost, latanoprost, travoprost, and / or unoprostone.

[0171] Other examples of drugs include, but are not limited to, betamethasone, cortisone, dexamethasone, dexamethasone 21-phosphate, methylprednisolone, prednisolone 21-phosphate, prednisolone acetate, prednisolone, fluroometholone, loteprednol, medrysone, fluocinolone acetonide, triamcinolone acetonide, triamcinolone, triamcinolone acetonide, beclomethasone, budesonide, flunisolide, fluorometholone, fluticasone, and fludrocol. diflunisal, etodolac, fenoprofen, flurbiprofen, indomethacin, ketoprofen, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, oxaprozin, piroxicam, salsalate, thiazolone ... Anti-inflammatory agents, including glucocorticoids and corticosteroids, such as nonsteroidal anti-inflammatory agents, including daquinoline and tolmetin; COX-2 inhibitors, such as celecoxib, rofecoxib, and valdecoxib; anti-inflammatory drugs, such as tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, cephalexin, oxytetracycline, chloramphenicol, rifampicin, ciprofloxacin, tobramycin, gentamicin, erythromycin, penicillin, sulfonamides, sulfadiazine ... Anti-infectives or antibacterials such as sulfacetamide, sulfamethizole, sulfisoxazole, nitrofurazone, sodium propionate, aminoglycosides, antibiotics including gentamicin, tobramycin, amikacin, and streptomycin; fluoroquinolones such as ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, norfloxacin, and ofloxacin; bacitracin, erythromycin, fusidic acid, neomycin, polymyxin B, gramicidin, trimethoprim, and sulfacetamide;Antifungal agents such as amphotericin B, caspofungin, clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole, terbinafine, nystatin, and miconazole; antimalarials such as chloroquine, atovaquone, mefloquine, primaquine, quinidine, and quinine; antimycobacterial agents such as ethambutol, isoniazid, pyrazinamide, rifampin, and rifabutin; and / or anthelmintic agents such as albendazole, mebendazole, thiobendazole, metronidazole, pyrantel, atovaquone, iodoquinaol, ivermectin, paromycin, praziquantel, and trimetrexate.

[0172] Other examples of drugs include, but are not limited to, antiviral agents such as idoxuridine, trifluorothymidine, acyclovir, cidofovir, famciclovir, ganciclovir, valacyclovir, valganciclovir, vidarabine, trifluridine, and foscarnet; protease inhibitors such as ritonavir, saquinavir, lopinavir, indinavir, atazanavir, amprenavir, and nelfinavir; nucleotide / nucleoside / non- Nucleoside reverse transcriptase inhibitors, such as abacavir, ddl, 3TC, d4T, ddC, tenofovir and emtricitabine, delavirdine, efavirenz and nevirapine; other antiviral agents, such as interferon, ribavirin and trifluridine; antibacterial agents, including carbapenems such as ertapenem, imipenem and meropenem; cephalosporins, such as cefadroxil, cefazolin, cef Dinil, cefditoren, cephalexin, cefaclor, cefepime, cefoperazone, cefotaxime, cefotetan, cefoxitin, cefpodoxime, cefprozil, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefuroxime and loracarbef; other macrolides and ketolides such as azithromycin, clarithromycin, dirithromycin and telithromycin; amoxicillin, Penicillins (with and without clavulanic acid), including ampicillin, pivampicillin, diclosaxillin, nafcillin, oxacillin, piperalicin, and ticarcillin; tetracyclines, such as doxycycline, minocycline, and tetracycline; and / or other antibacterial agents such as aztreonam, chloramphenicol, clindamycin, linezolid, nitrofurantoin, and vancomycin.

[0173] Other examples of drugs include, but are not limited to, immunomodulators such as anti-allergy drugs including sodium cromoglycate, antazoline, methapyrilene, chlorpheniramine, cetirizine, pyrilamine, profenpyridamine; aldesleukin, adalimumab, azathioprine, basiliximab, daclizumab, etanercept, hydroxychloroquine, infliximab, leflunomide, methotrexate, mycophenolate mofetil, and sulfasalazine; antihistamines, such as azelastine, emedastine, loratadine, desloratadine, cetirizine, diphenhydramine, chlorpheniramine, dexchlorpheniramine, clemastine, cyproheptadine, fexofenadine, hydroxyzine, promethazine, and levocabastine; immunological drugs (e.g., vaccines and immunostimulants); mast cell stabilizers, such as cromolyn sodium, ketotifen, lodoxamide, nedocrimil, olopatadine, and pemirolast; ciliary body ablatives, such as cycloheximide, cycloheximide, cycloheximide, cycloheximide, cycloheximide; agents, such as gentimicin and cidofovir; and other ophthalmic agents such as verteporfin, proparacaine, tetracaine, cyclosporine, and pilocarpine; inhibitors of cell surface glycoprotein receptors; decongestants, such as phenylephrine, naphazoline, tetrahydrazoline; lipids or antihypertensive lipids; dopaminergic agonists and / or antagonists, such as quinpirole, fenoldopam, and ibopamine; vasospasm inhibitors; vasodilators antihypertensives; angiotensin-converting enzyme (ACE) inhibitors; angiotensin-1 receptor antagonists, e.g., olmesartan; microtubule inhibitors; molecular motor (dynein and / or kinesin) inhibitors; actin cytoskeleton regulators, e.g., cytochalasin, latrunculin, swinholide A, ethacrynic acid, H-7, and Rho-kinase (ROCK) inhibitors; remodeling inhibitors; modulators of the extracellular matrix, e.g., tert-butylhydroquinolone and AL-3037A;Adenosine receptor agonists and / or antagonists, such as N-6-cyclophenoxyadenosine and (R)-phenylisopropyladenosine; serotonin agonists; hormonal agents, such as estrogen, estradiol, progesterone hormone, progesterone, insulin, calcitonin, parathyroid hormone, peptides and vasopressin hypothalamic releasing factor; such as epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, transforming growth factor beta, somatotropin, fibronectin, connective tissue growth factor Growth factor antagonists or growth factors, including bone morphogenetic proteins (BMPs), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), insulin-like growth factor (IGF), and nerve growth factor (NGF); and / or cytokines, such as interleukins, CD44, cotilin, osteopontin, pleiotrophin, midkine, vascular endothelial growth factor (VEGF), and serum amyloids, such as serum amyloid A;

[0174] Other therapeutic agents include, but are not limited to, neuroprotective agents, including, for example, lubezole, nimodipine and related compounds, and blood flow enhancers, sodium channel blockers, glutamate inhibitors such as memantine, neurotrophic factors, nitric oxide synthase inhibitors; free radical scavengers or antioxidants; chelating compounds; apoptosis-related protease inhibitors; compounds that reduce new protein synthesis; radiation therapy agents; photodynamic therapy agents; gene therapy agents; gene modifiers; and dry eye medications, for example, cyclosporine A, analgesics, and sodium hyaluronate; alpha blockers, for example, doxazosin, prazosin, and terazosin; calcium channel blockers, for example, amlodipine, bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine, anticoagulants, including heparin and heparinoids such as heparin, dalteparin, enoxaparin, tinzaparin, and fondaparinux; other anticoagulants, such as hirudin, aprotinin, argatroban, bivalirudin, desirudin, lepirudin, warfarin, and ximelagatran; and / or antiplatelet agents, such as abciximab, clopidogrel, dipyridamole, optifibatide, ticlopidine, and tirofiban.

[0175] Other therapeutic agents include, but are not limited to, prostaglandin PDE-5 inhibitors and other prostaglandin agents, such as alprostadil, carboprost, sildenafil, tadalafil, and vardenafil; thrombin inhibitors; antithrombogenic agents antiplatelet aggregation agents; thrombolytic and / or fibrinolytic agents, such as alteplase, anistreplase, reteplase, streptokinase, tenecteplase, and urokinase; antiproliferative agents, such as sirolimus, tacrolimus, everolimus, zotarolimus, paclitaxel, and mycophenolic acid; hormone-related agents, including levothyroxine, fluoxymestrone, methyltestosterone, nandrolone, oxandrolone, testosterone, estradiol, estrone, etropipate, clomiphene, gonadotropins, hydroxyprogesterone, levonorgestrel, medroxyprogesterone, megestrol, mifepristone, norethindrone, oxytocin, progesterone, raloxifene, and tamoxifen; carmustine, lomustine, melphalan, Antineoplastic agents include alkylating agents such as cisplatin, fluorouracil 3, and procarbazine antibiotic-like agents such as bleomycin, daunorubicin, doxorubicin, idarubicin, mitomycin, and plicamycin; antiproliferative agents (e.g., 1,3-cis retinoic acid, 5-fluorouracil, taxol, rapamycin, mitomycin C, and cisplatin); antimetabolites such as cytarabine, fludarabine, hydroxyurea, mercaptopurine, and 5-fluorouracil (5-FU); immunomodulatory agents such as aldesleukin, imatinib, rituximab, and tositumomab; mitotic inhibitors such as docetaxel, etoposide, vinblastine, and vincristine; radioactive agents such as strontium-89; and / or other antineoplastic agents such as irinotecan, topotecan, and mitotane.

[0176] RPC Administration and Treatment Methods Also provided herein are methods and uses of cultured retinal progenitor cells prepared as a cell suspension and used as an allogeneic transplant to treat patients with retinal disease. For example, provided herein are cell-based therapies that include or consist of the use of cultured heterogeneous cell populations derived from immature mammals, such as human retina.

[0177] The cell populations and related compositions described herein can be provided to a subject or patient by a variety of different means. As a non-limiting example, they can be provided locally, e.g., at the site of actual or potential injury or disease. In some embodiments, the compositions can be provided using a syringe or needle to inject the composition into the site of potential or actual injury or disease. In other embodiments, the compositions are provided systemically, e.g., administered intravenously or into an arterial bloodstream. The particular route of administration will depend primarily on the location and nature of the disease or injury being treated or prevented. Thus, the methods described herein include providing the cell populations or compositions by any known and available method or route, including, but not limited to, intraocular, oral, parenteral, intravenous, intraarterial, intranasal, and intramuscular administration.

[0178] Determining appropriate dosages and treatment regimens is generally known in the art and can be readily accomplished based on information obtained from a physician.

[0179] As a non-limiting example, cell doses can range from about 300,000 to about 500,000 cells (e.g., 300,000, 310,000, 320,000, 330,000, 340,000, 350,000, 360,000, 370,000, 380,000, 390,000, 400,000, 410,000, 420,000, 430,000, 440,000, 450,000, 460,000, 470,000, 480,000, 490,000, or 500,000 cells) or 500,000 to 3,000,000 cells (e.g., 500,000, 600, ,000, 700,000, 800,000, 900,000, 1,000,000, 1,100,000, 1,200,000, 1,300,000, 1,400,000, 1,500,000, 1,600,000, 1,700,000, 1,800,000, 1,900,000, 2,000,000, 2,100,000, 2,200,000, 2,300,000, 2,400,000, 2,500,000, 2,600,000, 2,700,000, 2,800,000, 2,900,000 or 3,000,000 cells).

[0180] The observed efficacy results are broadly similar between both dose ranges. However, if the patient's eye has a weakened zonule, a larger cell dose (e.g., 2-9 million cells) may increase the risk of cells persisting in the visual axis, adhering to the posterior lens capsule, and / or invading the anterior chamber (pseudohypopyon). Furthermore, those skilled in the art will appreciate that the duration of graft survival may be proportional to the dose and, therefore, the original graft size.

[0181] The frequency of administration of allogeneic hRPCs into the vitreous cavity is important. In various embodiments, subsequent administrations (i.e., "readministration") can be performed in the same eye or in the other eye of the patient. Readministration into the other eye has been performed without subsequent immune sequelae in both animal models and in some patients, suggesting that readministration is well tolerated bilaterally (and possibly into the same eye, as has been performed up to three times in animals).

[0182] Implants may survive for a year or longer in patients with RP, but because implants tend to disappear from the vitreous after approximately 1 to 1.5 years, this suggests that re-administration within a time frame of approximately 1 to 2 years may not be too invasive and may, in fact, become the standard going forward in the majority of cases.

[0183] In any of the methods disclosed herein, treatment may involve a single treatment or multiple (e.g., two, three, four, five, six, or more) treatments. In particular, for preventative purposes, certain embodiments contemplate administering the purified cell population after a stress that could potentially cause retinal damage.

[0184] In one embodiment, the cell populations and compositions can be administered locally as a single injection into the vitreous or subretinal space of a subject.

[0185] While the compositions and methods described herein are not limited to any particular mechanism of action, exemplary mechanisms of action are diffusive and / or trophic. Evidence is consistent with the concept of trophic reprogramming of dying host cones, resulting in a switch from an apoptotic trajectory to regeneration of light-processing capacity. This can be direct or indirect. The involvement of other ocular tissues is not excluded. This mechanism allows for the placement of grafts containing a heterogeneous mixture of fetal neural retinal cells into the vitreous or subretinal space.

[0186] Vitreous placement enhances the diffusion-based therapeutic effect. This mechanism allows for the placement of a heterogeneous mixture of fetal neural retinal cells outside the visual axis and still treat the patient's macula. Furthermore, vitreous placement is used to significantly simplify the procedure, as this exemplary procedure may increase accessibility to needy patients worldwide. Furthermore, vitreous placement may aid in immune tolerance due to its remoteness from the vasculature. Those skilled in the art will appreciate that vitreous placement avoids the potential complications of subretinal surgery, avoids the risks of general anesthesia, and does not require the creation of a hole in the retina (retinotomy) (which carries the risk of retinal detachment and bleeding) and / or the need to perform a focal detachment of the patient's retina (which can result in photoreceptor damage or loss, retinal tears, bleeding, and total retinal detachment; in RP, detachment of the thin, atrophic, adherent retina is a difficult / risky procedure).

[0187] In some embodiments, cells are placed into the vitreous cavity using an appropriate needle size and length. Ideally, the syringe should have minimal dead space (e.g., 1 microliter) to improve delivery efficiency and avoid product waste due to retention in the syringe. The use of a short needle (e.g., 31G (gauge) 5 / 16 inch length or 30G 1 / 2 inch length) allows for maximum convenience (i.e., suitability for use in clinical or medical settings). However, the use of a longer needle length (e.g., 27G or 25G 5 / 8 inch length) allows for optimal placement further posteriorly (backward) in the vitreous, closer to the macula (used under surgical vision). Determining the appropriate needle size and length is within the level of proficiency of a person skilled in the art. When selecting the appropriate needle size and length, it is important that cell viability remains above the required threshold after the cells pass through the needle.

[0188] Cell placement in the anterior vitreous is simple and allows for maximum safety and convenience. In contrast, placement in the posterior vitreous (near the posterior pole) requires direct visualization of the needle tip to avoid retinal penetration injury. However, this can improve overall treatment outcomes and represent optimal placement and efficacy.

[0189] Retinal cell replacement is possible but not required for clinical efficacy; donor cell migration to the retina is possible but not required for clinical efficacy; donor cell integration into the retinal network is possible but not required for efficacy; donor cell integration into the outer nuclear layer / macula of the host retina is possible but not required for efficacy; and / or donor cell integration within the retina is possible but not required for sustained graft survival.

[0190] In some embodiments, RPC cells are injected into the vitreous cavity, without the need for vitrectomy or subretinal surgery, if necessary. However, some embodiments may involve the optional use of one or more of vitrectomy, central vitrectomy, and / or vitreous dissolving agents to remove the vitreous gel and optimize the mobility and penetration of the injected cells into the posterior vitreous (e.g., an optimal location near the posterior pole of the eye). In some cases, the use of surgical vitrectomy can enhance cell placement within the eye.

[0191] The cells can be implanted (e.g., injected) into the subretinal space, or can be implanted (e.g., injected) into the eye using any standard intraocular injection procedure, for example, subcutaneously or using an oblique insertion route, and in some embodiments, no retinotomy, intraocular gas, or silicone oil is required.

[0192] Alternatively, anterior chamber paracentesis can be performed as needed depending on the circumstances, as determined by one of skill in the art. In some embodiments, there is no need for suturing of the globe during and / or after the procedure.

[0193] Any of the methods disclosed herein may include administering the composition directly to the vitreous cavity under topical anesthesia, without requiring systemic immunosuppression of the subject.Furthermore, tissue typing of the implant and matching with the patient or subject are not required, although if desired, this can be done using, for example, any tissue typing and matching technique known to those skilled in the art.

[0194] As described herein, any of the methods described herein can only use topical anesthesia, for example, do not use local anesthesia, regional anesthesia, or general anesthesia.However, in some cases, local anesthesia, regional anesthesia, or general anesthesia can be used in addition to or instead of administration.The examples of suitable local anesthetics suitable for use in the methods disclosed herein include, but are not limited to, meplicaine, proparacaine, prilocaine, ropivacaine, benzocaine, bupivacaine, butamben picrate, chloroprocaine, cocaine, dibucaine, dimethisoquin, dyclonine, etidocaine, hexylcaine, ketamine, lidocaine, mepivacaine, pramoxine, procaine, tetracaine, salicylic acid, and their derivatives, esters, salts, and mixtures.

[0195] In certain embodiments, anti-inflammatory and / or immunosuppression (i.e., systemic immunosuppression) is not required. Moreover, clinical experience supports that none is necessary, as in some cases graft survival is observed for many months, e.g., up to and beyond one year.

[0196] However, if necessary, anti-inflammatory and / or immunosuppressive treatment can be included as post-operative drops. For example, patients can be treated with topical steroid eye drops after injection, tapered for 1 week, or, if clinical evidence of persistent post-procedure inflammation is demonstrated after up to 2 weeks, treated with topical steroid eye drops after injection.

[0197] In alternative embodiments, bed rest is not required after surgery and / or there is no need for "prone" positioning. These methods can be performed as outpatient procedures and may not require any overnight hospital stay.

[0198] In some embodiments, during administration, the patient's head is tilted back as horizontally as possible from a reclined seated position to maximize the placement of the injected cells within the vitreous gel in the posterior pole of the eye, the most important part of the retina for vision. The patient should maintain this position for approximately 30 minutes or longer, as long as the patient can tolerate. Furthermore, after administration, the patient should spend time at home lying on their back and looking up.

[0199] Any of the compositions and methods described herein involve or use a heterogeneous mixture of fetal neural retinal cells (e.g., retinal progenitor cells) to treat, ameliorate, or prevent a retinal disease or condition, for example, Usher's disease, retinitis pigmentosa (RP), degenerative retinal disease, age-related macular degeneration (AMD), wet AMD or dry AMD, geographic atrophy, retinal photoreceptor disease, diabetic retinopathy, cystoid macular edema, uveitis, retinal detachment, retinal damage, macular hole, macular telangiectasia, traumatic or iatrogenic retinal damage, ganglion cell or optic nerve cell disease, glaucoma or optic neuropathy, retinopathy of prematurity, retinal vascular occlusion, or ischemic retinal disease such as ischemic optic neuropathy; or to improve light-adapted (daytime) vision; or to improve corrected visual acuity, or improve macular function, or improve visual field, or improve dark-adapted (night) vision.

[0200] Similarly, any of the compositions or methods described herein can be used to provide rapid results, an increase in best-corrected visual acuity, improved macular function, and / or potentially the preservation or restoration of central fixation.

[0201] The use or practice of any of the compositions and methods disclosed herein results in a variety of systemic benefits, such as a change in the treated individual's appearance; a sense of improved visual ability; increased independence from hospital visits; an improved sense of well-being; and / or improved activities of daily living, likely due to physical improvements that may be related to the effects of light on circadian rhythms, pituitary function, hormone release, vascular tone, etc.

[0202] In alternative embodiments, the use or practice of any of the compositions and methods disclosed herein does not result in the development of unwanted cell growth, e.g., tumors; infections, e.g., endopthalmitis, which are a risk for any intraocular procedure; disease transmission (although prion or mad cow disease can be difficult to eliminate); uveitis and / or acute graft rejection; elevated intraocular pressure; angle closure; hypotension (hypotony); retinal detachment; and / or neovascularization.

[0203] The uses and methods described herein can rapidly and sustainably restore and / or protect the clinically significant visual function of the retina in mammalian subjects, including but not limited to, improved light-adapted (daytime) vision, increased best-corrected visual acuity, improved macular function, protection or restoration of central fixation, improved visual field, improved dark-adapted (nighttime) vision, increased or improved sensitivity to sound, and improved visual acuity of the contralateral eye.Other changes can include various systemic benefits, such as changes in appearance due to physical improvements, which can be related to the effects of light on circadian rhythm, pituitary function, hormone release, and vascular tone; a sense of improved visual ability; improved independence from hospital visits; a sense of improved health; and / or improved activities of daily living.Such visual changes can be measured by methods known in the art.

[0204] Visual benefit may be rapid, occurring within one week of treatment, or may occur as a gradually increasing benefit over a longer period of time. Retinal cell replacement and / or migration of donor cells to the retina, retinal network, or outer nuclear layer or macula may occur, but is not required for clinical efficacy; migration of donor cells to the retina may occur, but is not required for clinical efficacy.

[0205] Measurement of visual changes, including visual improvement, resulting from treatment with the retinal progenitor cell compositions disclosed herein can be accomplished using standard ophthalmic examination techniques, including, but not limited to, fundus examination, best corrected visual acuity (BCVA), IOP, slit lamp examination, fluorescein angiography (FA), optical coherence tomography (OCT), stereo fundus photography, electroretinography (ERG), cone flicker electroretinography, perimetry (visual field), microperimetry, dark adaptation, maze negotiating skill, optokinetic / optokinetic response, pupillary reflex, visual evoked potential (VIP), and adaptive optics scanning laser ophthalmoscopy (AOSLO).

[0206] In vivo animal data also suggest that intravitreal RPCs are a means of affecting multiple cell types in the diseased retina, including, but not limited to, Müller cells (enhanced activation and / or increased local expression of glutamine synthetase (GS) in retinal degeneration); the vascular compartment in diabetic retinopathy (less vascular permeability (leakage) and / or less ischemia due to reduced intraretinal VEGF levels); enhanced recruitment of macrophages in retinal degeneration; increased local expression of bFGF (a neurotrophic factor) in retinal degeneration; and decreased expression of caspase 3 (indicating less retinal cell death). Thus, administration of RPCs may be useful in a variety of other retinal diseases, disorders, and conditions.

[0207] Furthermore, preliminary evidence of a crossover treatment effect has been observed in terms of signs of efficacy in the uninjected fellow eye. Specifically, this was observed in RCS rats (photoreceptor histological rescue and ERG recordings) and in a subset of patients (visual acuity testing), likely evidence of a "humoral" treatment effect that may extend beyond the injected eye. This effect could potentially be the result of cytokine and / or exosome diffusion through the blood circulation, immune modulation, or both.

[0208] Similarly, in vivo animal data suggest that a single intravitreal injection of osteopontin (OPN) alone reproduces some, but not all, of the therapeutic effects mediated by hRPCs. However, the effects of single administrations of pleiotrophin (PTN) and / or midkine differ from these findings with OPN in terms of the timing and specific responses of retinal cell populations.

[0209] In vivo data in animals also suggest that a single intravitreal injection of RPC-derived exosomes can, to some extent, reproduce the therapeutic effects mediated by hRPCs.

[0210] Kit and Instructions Kits containing any of the compositions described herein (e.g., a heterogeneous mixture of fetal neural retinal cells) suitable for use in any of the methods disclosed herein (e.g., treating a retinal disease or condition or generating or isolating a heterogeneous mixture of fetal neural retinal cells), along with instructions for their use, are also provided. Kits containing compositions, articles of manufacture, or cell mixtures or cultures (e.g., a heterogeneous mixture of fetal neural retinal cells) are also provided, and optionally, the kits further include instructions for carrying out any of the methods described herein.

[0211] The kits may also include cell populations containing mammalian retinal progenitor cells described herein, whether provided as cells in culture, as fresh or frozen cells, or as cells formulated as a composition for administration to a subject. Similarly, the kits may further include instructions for carrying out any of the methods described herein. In some embodiments, such kits may additionally contain an agent (e.g., an antibody or oligonucleotide primer) that binds to one or more markers of retinal progenitor cells described herein and / or a basal or conditioned medium. For example, a suitable kit may include a first container containing an antibody specific to one or more markers, the antibody adapted for isolation or detection, for example, by conjugation with a fluorescent marker or magnetic beads, and a second container containing a basal or conditioned medium. The kits may further include one or more additional reagents useful for preparing the cell populations provided herein, such as cell culture medium, cell culture dishes coated with an extracellular matrix, and / or enzymes suitable for tissue processing. The kit may also include instructions for using the kit to isolate, purify, and / or expand a retinal progenitor cell or cell population obtained from a tissue sample. Similarly, the kit may further include a means for obtaining a tissue sample from a patient or donor and / or a container for holding the obtained tissue sample.

[0212] Animal applications Any of the compositions and methods described herein can also be used in animal applications, such as for the growth of feline RPCs and therapeutic applications to the retina in dystrophic cats and other animals, including any mammalian pet, common domesticated and rare wild mammal species, zoo animals, farm animals, and sports animals (e.g., racing dogs or racehorses).

[0213] As a result of extensive inbreeding, there are several domesticated animals that carry the gene that causes blindness. These include cats, dogs, and horses, and possibly other species.

[0214] Similarly, there are retinal diseases and injuries occurring in wild and domestic animals that would benefit from treatment using the compositions and methods described herein.

[0215] Manufactured articles, implants and artificial organs Implants and artificial organs, bioreactor systems, cell culture systems, plates, dishes, tubes, bottles and flasks, etc., containing one or more of the compositions described herein containing a heterogeneous mixture of fetal neural retinal cells are also provided.

[0216] By way of non-limiting example, bioreactors, implants, stents, artificial organs, or similar devices containing a heterogeneous mixture of fetal neural retinal cells are further provided herein; see, e.g., U.S. Patent Nos. 7,388,042; 7,381,418; 7,379,765; 7,361,332; 7,351,423; 6,886,568; 5,270,192; and U.S. Patent Application Publication Nos. 20040127987; 2008011 Implants similar to or described in Patent No. 9909 (which describes an ear implant); Patent No. 20080118549 (which describes an ocular implant); Patent No. 20080020015 (which describes a bioactive wound dressing); Patent No. 20070254005 (which describes heart valve bioprostheses, vascular grafts, and meniscus implants); Patent No. 20070059335; and Patent No. 20060128015 (which describes a liver implant).

[0217] Enumeration of Embodiments The present invention can be defined by reference to the following exemplary embodiments:

[0218] 1. A method for isolating primary retinal cells obtained from a human sample, comprising: To generate suspensions of dissociated cells and cell clusters, a) processing a sample of human retinal tissue obtained from a human donor between about 12 weeks and about 28 weeks of gestation; b) mechanically dissociating the obtained sample; c) determining the viability and quantity of primary retinal cells obtained from the sample; d) confirming the morphology of the obtained primary retinal cells; A method comprising:

[0219] 2. The method of embodiment 1, wherein the human retinal tissue is obtained from one or a pair of human eyes.

[0220] 3. The method of embodiment 2, wherein the eyeball(s) have normal morphology, including an intact sphere, a clear cornea, a normal shape, or any combination thereof.

[0221] 4. The method of embodiment 1, wherein immediately after tissue collection from the human donor, the human retinal tissue is preserved in RPMI-1640 medium containing L-glutamine and stored on ice.

[0222] 5. The method of any one of embodiments 1 to 4, wherein the preserved human retinal tissue is delivered and used within a defined period of time from collection.

[0223] 6. The method of embodiment 5, wherein the prescribed period of time comprises about 7 to about 26 hours.

[0224] 7. Step (a) a) After tissue collection, remove the eyeball(s) from the RPMI-1640 medium and rinse them 1-5 times with ice-cold phosphate-buffered saline (PBS) supplemented with antibiotics; b) removing the optic nerve and mesenchymal tissue from the eyeball and removing all extraocular cells; c) Washing the eyeball with ice-cold PBS supplemented with antibiotics; d) using a needle to puncture the edge of the sphere; e) making circumferential cuts along the edges with microsurgical scissors; f) Removal of the lens, cornea, and associated vitreous body; g) dissociating the retina(s) from the retinal pigment epithelium (RPE) layer to generate an isolated retina; h) Placing the isolated retina(s) in a Petri dish containing ice-cold medium or PBS supplemented with antibiotics 2. The method of embodiment 1, comprising:

[0225] 8. Step (b) comprises: a) Transfer of the retina(s) into the cone canal; b) mechanically dissociating the retina(s) to produce dissociated retinas; c) washing the Petri dish with serum-free medium supplemented with antibiotics and transferring the medium containing any remaining dissociated retina to the conical tube containing the dissociated retina(s); d) pelleting the dissociated retina(s) by centrifugation; and e) Removing the supernatant 2. The method of embodiment 1, comprising mechanically dissociating the cells by

[0226] 9. The method of embodiment 8, wherein mechanical dissociation of the retina is carried out through trituration with a sterile pipette.

[0227] 10. The method of embodiment 8, wherein the dissociated retina is pelleted by centrifugation at 10-1000 g at 1-50° C. for a period of 0-30 minutes.

[0228] 11. Step (c) is a) resuspending the pelleted retinal tissue from step (b) in ice-cold serum-free medium supplemented with antibiotics; b) determining the quantity and viability of retinal cells and retinal cell clusters obtained from mechanically dissociated retinal tissue; c) seeding the cells into fibronectin-coated cell culture flasks containing serum-free medium supplemented with antibiotics; d) Incubating the flask containing the retinal cells at 10-50°C. 2. The method of embodiment 1, comprising:

[0229] 12. The method of embodiment 11, wherein the amount and viability of the cells are measured by an NC-200 cell counter.

[0230] 13. The method of embodiment 11, wherein the number of cells counted is from about 1 to about 1,000,000,000.

[0231] 14. The method of embodiment 11, wherein the percentage of viable counted cells is about 10 to about 100.

[0232] 15. The method of embodiment 11, wherein the flask is seeded with about 1 to about 1,000,000,000 cells.

[0233] 16. The method of embodiment 11, wherein the incubation of the flask containing the retinal cells is at 37°C under 0-30% CO2 and 0-50% O2.

[0234] 17. The method of embodiment 1, wherein step (d) comprises confirming that the retinal cells seeded in the cell culture flask consist of retinal cell clusters containing about 1 to about 100 cells.

[0235] 18. The method of any one of embodiments 1 to 17, wherein the antibiotic used to supplement the PBS or serum-free medium is gentamicin.

[0236] 19. The method of any one of embodiments 1 to 18, wherein the antibiotic is used at a concentration of about 0 to about 10,000 μg / mL.

[0237] 20. Serum-free medium is a) Advanced DMEM / F12 b) N-2 adjuvant; c) EGF (recombinant human epidermal growth factor), d) bFGF (basic fibroblast growth factor), and e) GlutaMAX I 20. The method of any one of embodiments 1 to 19, comprising:

[0238] 21. A method for culturing isolated primary human retinal cells to generate a population of non-immortal human retinal progenitor cells, comprising: a) culturing a suspension of isolated primary retinal cells in xeno-free fibronectin, ornithine, polylysine, or laminin-coated culture flasks or plates in serum-free medium at standard oxygen levels for approximately 4-6 passages; b) then culturing the suspension in serum-free medium at low oxygen levels for approximately 3-6 additional passages, wherein the cells are passaged at 40%-90% confluence, and at each passage, the cells are treated with an enzyme to dissociate the cells and fresh culture medium is added; and c) then cryopreserving the cells, thereby generating a population of non-immortal human retinal progenitor cells. A method comprising:

[0239] 22. The method of embodiment 21, wherein after the subsequent step of culturing the suspension at low oxygen levels, the cells are grown at standard oxygen levels for a period of time without passaging.

[0240] 23. The method of embodiment 21, wherein the period between passagings is 3 to 5 days.

[0241] 24. The method of embodiment 21, wherein the enzyme solution used to dissociate the cells comprises trypsin or an equivalent.

[0242] 25. The method of embodiment 21, wherein the cells are dissociated at passage 1 using an enzyme solution containing trypsin or equivalent and EDTA in a 1:4 ratio at 37°C for 6 to 10 minutes.

[0243] 26. The method of embodiment 21, wherein the cells at passage 2 are dissociated using an enzyme solution containing trypsin or equivalent and DPBS in a ratio of 1:1:3 at 37°C for 4 to 8 minutes.

[0244] 27. The method of embodiment 21, wherein the cells are dissociated at passage 3 and all further passages using an enzyme solution containing trypsin or equivalent, EDTA, and DPBS in a 1:1 ratio at 37°C for 4 to 8 minutes.

[0245] 28. The method of embodiment 21, wherein dissociation is stopped by adding an excess amount of DMEM or PBS.

[0246] 29. The method of embodiment 21, wherein cell number and viability are determined after dissociation.

[0247] 30. The method of embodiment 21, wherein cell number and viability are determined by an NC-200 cell counter.

[0248] 31. The cryopreservation in step (c) a) enzymatic dissociation of cells using 1:1 trypsin or equivalent and DPBS; b) stopping the dissociation with excess DMEM or PBS; c) pelleting the cells by centrifugation at 10 to 10,000 g for 1 to 30 minutes; d) resuspending the cells in serum-free medium and determining total cell number and viability; e) Adding cryopreservation medium to achieve a final DMSO concentration of 5-30%; f) 0.2 to 100 x 10 6 aliquoting the cells into individual cryovials; g) freezing each vial at -80°C for 6 to 72 hours; and h) Placing each vial of cells in liquid N2 22. The method of embodiment 21, wherein the method is performed by

[0249] 32. The method of embodiment 21, wherein the cells and / or cell clusters are cultured with supplements or additives that support cell survival or growth.

[0250] 33. The method of embodiment 32, wherein the supplements or additives that support cell survival or growth are selected from the group consisting of L-glutamine, human recombinant growth factors consisting of EGF and bFGF (Invitrogen), and other growth factors. [Example]

[0251] Example 1 Isolation of primary retinal cells: Protocol A Isolation of primary human retinal cells is prepared according to a specifically optimized protocol for a transport interval of 4.5 to 21.5 h, where the transport interval is measured from the time the tissue is harvested to the time the donor tissue is received. 1. Transport one or a pair of eyeballs from a 17-18 week gestational fetus in a 15 ml tube containing RPMI-1640 medium with L-glutamine (BioWhittaker) on ice and deliver within 4.5-21.5 hours. Upon receipt, inspect the eyeball(s) for gross abnormalities: the globe is intact, the cornea is clear, and the eyeball has a normal shape. Steps 2-8 are performed using sterile technique in a laminar flow hood. 2. Rinse the entire eyeball three times (in three different tubes) with 40 ml (in a 50 ml tube) of cold PBS containing antibiotics. 3. The optic nerve and remaining mesenchymal tissue were removed. This procedure was taken to avoid possible contamination of the retinal isolate with brain-derived cells. One more rinse with cold PBS containing antibiotics was performed. 4. Under a dissecting microscope, 5 / 8 A 1 ml syringe with a needle is used to puncture the limbus, and the globe is opened circumferentially by cutting along the limbus with microsurgical scissors, and the cornea, lens, and associated vitreous are removed. The retina is carefully teased away from the RPE and collected in a small Petri dish containing approximately 2 ml of cold DMEM / F12. 5. Using a 1 mL tip, carefully separate the retina into small pieces and place them in a Petri dish (2-5 times), then transfer to a 15 mL cold conical-bottom tube. Rinse the Petri dish 2-3 times with 1 mL of cold PBS, add to the 15 mL tube, and centrifuge at 1000 rpm (179 x g) for 5 minutes. Remove the supernatant completely using a 10 mL pipette and a polished glass pipette. 6. Gently add 0.8 mL of undiluted TrypLE Express (Invitrogen) over 40 seconds at room temperature, slowly pipette up and down (approximately 10 times) using a 1 mL tip, neutralize the TrypLE Express by adding 10 mL of cold fresh medium (serum-free), spun down at 1000 rpm (179 g) for 4 minutes, remove the supernatant, resuspend the pellet in 1.5 mL of cold fresh medium (SM), pipette up and down approximately 10 times using a polished glass pipette, add an additional 6.5 mL of medium, and determine cell viability and cell number by Trypan Blue (Invitrogen) staining and count by Countess (Invitrogen) or manually; approximately 1.3 × 10 6 cells / ml, about 92% were viable cells, and about 10 × 10 6 Approximately 80% are small / medium clusters, with clusters / whole cells. Cells are seeded into two fibronectin-coated T75 plates (see Example 5) and then incubated at 37°C under 5% CO2, 3% or 20% O2 (optionally incubate at 37°C, 5%-10% CO2, 1%-20% O2). NOTE: Defined cell count. · Single cell: Approximately 6-8 μm, containing one cell. Small clusters: approximately 15-40 μm, containing approximately 2-30 cells. Medium clusters: approximately 40-100 μm, containing approximately 30-80 cells. Large clusters: approximately 100-150 μm, containing >80 cells. Of the resulting cell population, approximately 80-90% were small or medium clusters, approximately 9-18% were single cells, and approximately 1-2% were large clusters. If each small / medium cluster is counted as one, the total number of cells is approximately 10 × 10 6 is. If a single cell is counted as one, the total number of cells is approximately 240 × 10 6 is. 7. Total procedure: 45 minutes to 1 hour 10 minutes (up to 2 hours if necessary). 8. After approximately 1.5 hours, 90% of the cells will have settled to the bottom (if the tissue is fresh, e.g., after 4.5 hours on ice, otherwise, e.g., after 21.5 hours on ice, they will settle to the bottom in approximately 6 hours), 90% will be small clumps, and 10% will be single cells. Generally, 90% will be live (good), and the cell density will be >10% confluent as assessed by IncuCyte (about 20% is better). Take a photo.

[0252] Example 2 Isolation of primary retinal cells: Protocol B Isolation of primary human retinal cells is performed according to a specifically optimized protocol for a transport interval of 7-26 h, where the transport interval is measured from the time the tissue is harvested to the time the donor tissue is received. 1. Transport one or a pair of eyeballs from fetal tissue donations between 17 and 20 weeks of gestation in a 15 ml tube containing RPMI-1640 medium with L-glutamine (BioWhittaker) on ice and deliver within a 7-26 hour transport window. The protocol may also be useful for a wider transport window. Upon receipt, inspect the eyeball(s) for gross abnormalities: the globe should be intact, the cornea should be clear, and the globe should have a normal shape. Add 50 μg / mL gentamicin to the RPMI-1640 and L-glutamine transport medium to prevent potential tissue contamination. Steps 2-8 are performed using aseptic technique in a laminar flow biosafety cabinet. 2. Rinse the intact eyeball three times (in three different tubes) with 40 ml (in a 50 ml tube) of cold PBS containing an antibiotic. Use 30 μg / mL of gentamicin. Gentamicin is used instead of penicillin or streptomycin to avoid excluding patients with antibiotic allergies. 3. Remove the optic nerve and remaining mesenchymal tissue from the eye(s) to avoid possible contamination of the retinal isolate with extraocular cells. Rinse once more with cold PBS containing antibiotics. 4. Under a dissecting microscope, 5 / 8 Using a 1 ml syringe with a needle, puncture the edge of the globe, cut along the edge using microsurgical scissors, open the globe circumferentially, remove and discard the cornea, lens, and associated vitreous. Carefully tear the retina away from the underlying RPE layer and transfer it to a small Petri dish containing approximately 2 ml of cold complete medium containing gentamicin (gentamicin 30 μg / ml). 5. Transfer the retina to a 15 mL conical tube. Break the retina into small pieces using gentle trituration (4-8 times) with a 1 mL pipette tip. If any retinal tissue remains in the Petri dish, rinse the dish 1-2 times with 1 mL of cold complete medium containing gentamicin and add it to the 15 mL tube containing the retinal tissue. Transfer the 15 mL tube and centrifuge at 140 x g for 3 minutes at 4°C, aspirate, and completely remove the supernatant. 6. Resuspend the pellet in 1.0 mL of cold, fresh medium containing gentamicin using a 1 mL pipette tip, gently pipette the suspension 4-5 times, and add an additional 15 mL of medium. Determine cell viability and cell number using the clump cell counting method on the NC-200. This method allows for accurate cell counts while maintaining cell clusters, which can be important for initial cell culture and tissue conversion. Cell viability is expected to fall within the range of 68-85%, with viable cell counts of approximately 73-147 x 10. 6The cells are seeded onto 3 x T25 (or 1-2 T75) flasks (see Example 5) pre-coated with fibronectin, then incubated at 37°C in 5% CO2, 20% O2. (Note: The 20% is for Step 1: Tissue to Seed Bank, which can also be done under hypoxic conditions; however, the goal here was to keep the new product as close as possible to the previous product grown under 20% oxygen. Step 2: Seed Bank to Production Bank, performed using hypoxic 3% culture to extend cell growth.) 7. Examine the cells under a microscope: the culture is expected to consist mainly of small to medium sized clusters, plus some single cells (the latter are likely to be non-viable). 8. Duration of the entire isolation procedure: approximately 30-60 minutes (this protocol, which specifically omits enzymes, is significantly faster and simpler to perform than enzyme-based isolation protocols).

[0253] Example 3 Cell Culture: Protocol A Human retinal progenitor cells were cultured from retinal cells isolated as described in Example 1: 1. Medium change: Change 90% of the medium every 2 days. 2. Passaging: Passage cells at 60-80% confluence, or 40-90% confluence as needed, with TrypLE Express (Invitrogen), trypsin or equivalent as needed, or TRYP-LE EXPRESS or equivalent, diluted 2-fold (0.125% equivalent), and incubated at 37°C for 5-6 minutes. Dissociation is stopped by adding 10 ml of old medium or cold PBS. Cell viability and cell number are determined by Trypan Blue (Invitrogen) staining and counted manually or by Countess (Invitrogen), with cell viability >90%. Plate cells onto new fibronectin-coated flasks / plates at a density of 1-6.7 x 10 4 / cm 2 (initial passage 6.7 × 10 4 clusters / cm 2), late progeny: 2×10 4 / cm 2 ) and sow. 3. Cell Freezing: Cells are harvested with TrypLE Express (Invitrogen), trypsin or equivalent as needed, or TRYP-LE EXPRESS or equivalent, 2x diluted (0.125% equivalent), and incubated at 37°C for 5-6 minutes. Dissociation is stopped by adding 10 ml of old medium or cold PBS. Centrifuge at 1000 rpm (179 x g) for 5 minutes and resuspend cells in fresh medium or cold PBS. Cell viability and cell number are determined by Trypan Blue (Invitrogen) staining and counted by Countess (Invitrogen) or manually. Centrifuge at 1000 rpm (179 x g) for 5 minutes and resuspend cells in cell freezing medium and count 0.5-5 x 10 6 Cells are aliquoted into individual cryovials (Greiner), placed in Cryo 1°C freezing containers (NALGENE), placed in a -80°C freezer overnight (or longer, <2 weeks), and transferred to a liquid nitrogen tank. 4. Thawing cells: Remove cells from liquid nitrogen and place in a 37°C water bath for 2-3 minutes until crystals disappear. Immediately transfer to a cold 15ml conical-bottom tube using a 1ml tip. Rinse the vial twice with cold fresh medium. Slowly add 12ml of cold fresh medium to the 15ml tube, the first 1ml dropwise, and shake gently. Centrifuge at 800 rpm (115g) for 3 minutes. Discard the supernatant, resuspend the cell pellet in fresh medium, and determine cell number and viability as described above. Seed into a new coated flask and incubate under the conditions described above. 5. Preparation of cells for transplantation: Cells are harvested with TrypLE Express (Invitrogen), trypsin or equivalent as needed, or TRYP-LE EXPRESS or equivalent, diluted 2-fold (0.125% equivalent), and incubated at 37°C for 5-6 minutes. Dissociation is stopped by adding 10 ml of old medium or cold PBS. After centrifugation at 1000 rpm (179 x g) for 5 minutes, cells are resuspended in 10 ml of cold HBSS. Cell viability and cell number are determined by Trypan Blue (Invitrogen) staining and counted by Countess (Invitrogen) or manually. After centrifugation at 1000 rpm (179 x g) for 5 minutes, cells are resuspended in cold HBSS. Cell suspension for transplantation, 0.5 x 10 cells in 100 μl of HBSS for patients, is used. 6 For cells, rats, prepare 30,000 cells in 2 μl of HBSS.

[0254] Example 4 Cell Culture: Protocol B Human retinal progenitor cells were cultured from retinal cells isolated as described in Example 2: 1. Medium exchange: 100% medium exchange, every 2 days except days 0-3. Open, closed, and semi-closed systems can all be used for medium exchange and cell passaging. If necessary, medium can be exchanged daily. 2. Passaging: Passage cells every 4-5 days at 15-95% confluence, or 40-95% confluence as needed. The method varies depending on the number of passages. Cells can also be passaged every 3-4 days or every 3-5 days. Passage 1: TrypLE Select (Invitrogen) + EDTA (Invitrogen), 1:4, incubation at 37°C for 7–8 min. Passage 2: TrypLE Select (Invitrogen) + EDTA (Invitrogen) + DPBS (Invitrogen), 1:1:3, incubated at 37°C for 5-6 minutes. Passage 3 and thereafter: TrypLE select (Invitrogen) + DPBS, 1:1, incubation at 37°C for 5–7 min. TrypLE Express, trypsin, or equivalent, or TRYP-LE EXPRESS or equivalent, diluted 2-fold (0.125% equivalent), can be used as needed. Dissociation of clusters is stopped by adding DMEM or PBS (10 ml). Cell viability and cell number are determined using an NC-200. Expected cell viability is >70%. Cells are plated onto new fibronectin-coated flasks / plates at 3–67 × 10 cells / ml. 4 / cm 2 (Early passage 67 × 10 4 / cm 2 , later passage: 3 × 10 4 / cm 2 ) and sow at a density of 10 ... 3. Cryopreservation: Cells are harvested using TrypLE Select / Express (Invitrogen), trypsin or equivalent as needed, or TRYP-LE EXPRESS or equivalent, at a 2-fold dilution (0.125% equivalent), and incubated at 37°C for 5-7 minutes. Dissociation is stopped by adding DMEM or PBS. Cells are then spun down at 490 x g for 7 minutes for 50 ml tubes and 700 x g for 8 minutes for 500 ml conical bottles, and resuspended in fresh medium. Cell viability and cell number are determined using an NC200. An equal volume of 2x cryopreservation medium (20% DMSO) is added to achieve a final 10% DMSO for the cell suspension. 0.5-10 x 10 6 Aliquot the cells into individual cryovials (Themofisher or similar), place them in Cryo 1°C freezing containers (NALGENE), place them in a -80°C freezer overnight (or longer, <2 weeks), and transfer them to a liquid nitrogen tank. 4. Thawing cells: Remove cells from liquid nitrogen and place in a 37°C water bath for 2-3 minutes until crystals disappear. Immediately transfer to a cold 15ml conical-bottom tube using a 1ml tip. Rinse the vial 1-2 times with cold fresh medium. Slowly add 9-12ml of cold fresh medium to the 15ml tube and centrifuge at 1200 rpm (300g) for 5 minutes. Discard the supernatant, resuspend the cell pellet in fresh medium, and determine cell count and viability as described above. Seed into a new coated flask and incubate under the conditions described above. 5. Preparation of cells for transplantation: Cells are harvested with TrypLE Express (Invitrogen), trypsin or equivalent as needed, or a two-fold dilution of TRYP-LE EXPRESS or equivalent (0.125% equivalent), and incubated at 37°C for 5-6 minutes. Dissociation is stopped by adding DMEM. The cell suspension is spun down at 300g for 5 minutes, and the cells are then resuspended in 0.5-3 ml of cold BSS Plus (or BSS / DPBS / HBSS). Cell viability and cell number are determined using Trypan Blue (Invitrogen) and counted by Countess (Invitrogen) or manually or by NC200. After spun down at 300g for 5 minutes, the cells are resuspended in cold BSS Plus (or BSS / DPBS / HBSS) to produce a dose appropriate for transplantation.

[0255] Example 5 Preparation of reagents and cell products Preparation of complete medium (serum-free) Medium for culturing human retinal progenitor cells was prepared using the following components: ·Advanced DMEM / F12(Invitrogen) DMEM / F12 (Invitrogen or other brands), or KnockOut DMEM / F12 (Invitrogen or other brands), or neurobasal (Invitrogen), or UltraCULTURE (Lonza), or ReNcell (Chemicon), or other equivalent media, as appropriate. N-2 supplement (Invitrogen), Xeno-free B27 (Invitrogen or other brands) or non-xeno-free B27, or Stempro (Invitrogen), or other equivalents, as appropriate. EGF (Recombinant Human Epidermal Growth Factor): Invitrogen, other brands as needed bFGF (basic fibroblast growth factor): Invitrogen, other brands as needed GlutaMAX I: Invitrogen, L-glutamine (Invitrogen or other brands) as needed Gentamicin (Invitrogen) for isolation and first passage (approximately 4-5 days)

[0256] Passaging enzymes: Versene solution: Thermo Fisher (Lifetech), used as described above in passages 1 and 2. Versene is an EDTA solution for use as a gentle, non-enzymatic cell dissociation reagent. Gibco® Versene solution (0.48 mM) is formulated as 0.2 g EDTA(Na4) per liter of phosphate-buffered saline (PBS). Preparation of cryopreservation medium

[0257] A medium for cryopreserving cultured human retinal progenitor cells was prepared containing: 90% complete medium 10% DMSO Flask coating Human plasma fibronectin (Invitrogen), ornithine, poly-lysine, laminin, or Matrigel as needed, in DPBS at a concentration of 1–5 μg / cm 2 Allow to coat for 1-3 hours at room temperature in the hood, then store at 4°C overnight or for up to 2 weeks. Rinse with Advanced DMEM / F12 before use.

[0258] Example 6 Additional Versions of Cell Culture Protocol B Human retinal progenitor cells were cultured from retinal cells isolated as described in Example 2: 1. Medium exchange: 100% medium exchange, changed every 2 days. Open, closed, and semi-closed systems are all useful for medium exchange and cell passaging. If necessary, the medium can be exchanged daily. 2. Passaging: Passage cells every 4-5 days at 15-95% confluence, or 40-95% confluence as needed. The method varies depending on the number of passages. Cells can also be passaged every 3-4 days or every 3-5 days. Passage 1: TrypLE Select (Invitrogen) + EDTA (Invitrogen), 1:4, incubation at 37°C for 7–8 min. Passage 2: TrypLE Select (Invitrogen) + EDTA (Invitrogen) + DPBS (Invitrogen), 1:1:3, incubated at 37°C for 5-6 minutes. Passage 3 and thereafter: TrypLE select (Invitrogen) + DPBS, 1:15 to 7 min, incubation at 37°C. TrypLE Express, trypsin, or equivalent, or TRYP-LE EXPRESS or equivalent, diluted 2-fold (equivalent to 0.125%), can be used as needed. Dissociation of the clusters is stopped by adding 10 ml of DMEM or PBS. 3. Dissociation: Dissociation of cell clusters is stopped by adding Advanced DMEM or PBS (10 ml). Cell viability and cell number are determined using NC-200. Expected cell viability is >70%. Cells are transferred to new fibronectin-coated flasks or cell stacks (CS) at 1–200 × 10 4 / cm 2 (Early passage: 2 × 10 6 / cm 2 , later passage: 1 × 10 4 / cm 2 ) and sow at a density of 10 ... 4. Cryopreservation: Cells are harvested using TrypLE Select / Express (Invitrogen), trypsin or equivalent as needed, or TRYP-LE EXPRESS or equivalent, at a 2-fold dilution (0.125% equivalent), with a 5-7 minute incubation at 37°C. Dissociation is stopped by adding DEME or PBS, and the cells are then spun down. For 50 ml tubes, cells are centrifuged at 490 x g for 7 minutes. For 500 ml conical bottles, cells are centrifuged at 700 x g for 8 minutes. Cells are resuspended in fresh medium. Cell viability and cell number are determined using an NC200. An equal volume of 2x cryopreservation medium (20% dimethyl sulfoxide (DMSO)) is added to achieve a final 10% DMSO concentration for the cell suspension. 0.5-10 x 10 6 Aliquot the cells into individual cryovials (Themofisher or similar), approximately 10 x 10 cells per mL of culture medium + 10% DMSO. 6 ~About 40×10 6 Cells are placed in a Cryo 1°C freezing container (NALGENE) and the container is placed in a -80°C freezer overnight (or longer, <2 weeks), then transferred to a liquid nitrogen tank. Alternatively, cells can be frozen using a Control Rate Freezer before transferring them to liquid nitrogen. 5. Thawing cells: Remove cells from liquid nitrogen and place in a 37°C water bath for 2-3 minutes until crystals disappear, then immediately place into a cold 15ml conical-bottom tube using a 1mL tip. Rinse the vial 1-2 times with cold fresh medium, then add 9-12mL of cold fresh medium to the 15ml tube. Spin down at 1200 rpm (300g) for 5 minutes. Discard the supernatant and resuspend the cell pellet in fresh medium as described above for Example 2, and determine cell number and viability. Seed the cells into a new coated flask or cell stack and incubate under the conditions described above. 6. Preparation of cells for transplantation: Cells are harvested with TrypLE Express (Invitrogen), trypsin or equivalent as needed, or TRYP-LE EXPRESS or equivalent, diluted 2-fold (0.125% equivalent), and incubated at 37°C for 5-6 minutes. Dissociation is stopped by adding complete medium, DMEM, or PBS. The cell suspension is spun down at 300g for 5 minutes, and the cells are then resuspended in 0.5-3 ml of cold BSS Plus (or BSS / DPBS / HBSS). Cell viability and cell number are determined using Trypan Blue (Invitrogen) and counted manually or using an NC200 by Countess (Invitrogen). The cells are spun down at 300g for 5 minutes, and the cells are resuspended in cold BSS Plus (or BSS / DPBS / HBSS) to produce a dose appropriate for transplantation.

[0259] Reagent / Cell Product Preparation:

[0260] Preparation of complete medium (serum-free): Advanced DMEM / F12 (Invitrogen) was used in this protocol. If desired, DMEM / F12 (Invitrogen or other brands), KnockOut DMEM / F12 (Invitrogen or other brands), neurobasal (Invitrogen), UltraCULTURE (Lonza), ReNcell (Chemicon), or other equivalent media may be used. · N-2 supplement (Invitrogen), xeno-free B27 (Invitrogen or other brand), non-xeno-free B27, or Stempro (Invitrogen), or other equivalent, as needed. EGF (Recombinant Human Epidermal Growth Factor): Invitrogen, other brands as needed. bFGF (basic fibroblast growth factor): Invitrogen, other brands as needed. GlutaMAX I: Invitrogen, L-glutamine (Invitrogen or other brands) as needed Gentamicin (Invitrogen) for isolation and first passage (approximately 4 days, but gentamicin can be used for longer).

[0261] Passaging enzymes: Versene solution: Thermo Fisher (Lifetech), used as described above in passages 1 and 2. Versene is an EDTA solution for use as a gentle, non-enzymatic cell dissociation reagent. Gibco® Versene solution (0.48 mM) is formulated as 0.2 g EDTA(Na4) per liter of phosphate-buffered saline (PBS).

[0262] Preparation of cryopreservation medium: ·90% fresh complete medium. · 10% DMSO (dimethyl sulfoxide) (Sigma, other brands as needed).

[0263] Flask Coating: Human plasma fibronectin (Invitrogen) was used. Ornithine, poly-lysine, laminin, or Matrigel can be used as alternatives, if desired. · Fibronectin is diluted in DPBS. 〇Concentration: 1~5μg / cm 2 Allow to coat at 4C overnight for up to 2 weeks or allow to coat at room temperature in a hood for 1-3 hours and store at 4C overnight or for up to 2 weeks. 〇Rinse with Advanced DMEM / F12 before use. *Flasks can be used without rinsing with Advanced DMEM / F12.

[0264] equivalent The details of one or more embodiments of the invention are described in the accompanying specification above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the exemplary methods and materials are now described.

[0265] The foregoing description has been presented for purposes of illustration only, and the present invention is not limited to the precise form disclosed, but rather is limited only by the scope of the appended claims.

[0266] Modifications can be made to the foregoing without departing from the basic aspects of the invention. While the present invention has been described in considerable detail with reference to one or more specific embodiments, those skilled in the art will understand that changes may be made to the embodiments specifically disclosed in this application and that these modifications and improvements will still fall within the scope and spirit of the invention. The invention illustratively described herein can suitably be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each example herein, the terms "comprising," "consisting essentially of," and "consisting of" can all be substituted for either of the other two terms. Accordingly, the terms and expressions used are used in descriptive terms and not limiting, and do not exclude equivalents of the features shown and described or portions thereof, with the understanding that various modifications are possible within the scope of the invention. Embodiments of the invention are set forth in the following claims.

Claims

1. 1. A method for isolating primary retinal cells from a human sample of one or a pair of human eyeballs obtained from a human donor, the one or pair of human eyeballs having normal morphology including an intact globe(s), a clear cornea, a normal shape or any combination thereof, the method comprising: (a) isolating a retinal sample comprising a plurality of primary retinal cells from the human sample within 8 hours after collection of the one or pair of human eyes from the human donor, wherein the human donor is a fetus between about 12 weeks and about 28 weeks of gestation; (b) mechanically dissociating a plurality of said primary retinal cells in said retinal sample isolated in step (a) through trituration with a sterile pipette without digesting said plurality of said primary retinal cells with a protease, thereby generating a suspension of dissociated cells and cell clusters; (c) determining the viability, quantity and morphology of the primary retinal cells obtained from the retinal sample, comprising: 6 Steps for generating viable primary retinal cells The method includes:

2. 2. The method of claim 1, wherein prior to step (a), the human sample after collection from the human donor is placed in a transport cell culture medium comprising RPMI-1640 or Advanced DMEM / F12 containing L-glutamine; and / or the transport cell culture medium comprises about 0.5 to 50 micrograms of gentamicin per milliliter.

3. 3. The method of claim 2, wherein the transport cell culture medium comprises 50 micrograms of gentamicin per milliliter.

4. Step (b) (i) transferring the retina sample to a tube; (ii) mechanically dissociating the retinal sample to generate a plurality of dissociated primary retinal cells; (iii) pelleting a plurality of the dissociated primary retinal cells by centrifugation; and (iv) Removing the supernatant. The method according to any one of claims 1 to 3, comprising:

5. Step (c) (i) resuspending the pelleted primary retinal cells from step (b) in culture medium supplemented with antibiotics at about 1-8° C.; (ii) seeding a plurality of said dissociated retinal cells into one or more coated cell culture flasks or plates containing a culture medium, said culture medium being supplemented with an antibiotic; (iii) incubating the plurality of dissociated retinal cells at 10-37°C; and (iv) determining the quantity and viability of primary retinal cells and retinal cell clusters The method according to any one of claims 1 to 4, comprising:

6. The number of viable primary retinal cells is approximately 30 × 10 6 ~Approx. 1×10 9 viable primary retinal cells, or about 73×10 to about 147×10 6 6. The method of claim 5, wherein the cells are viable primary retinal cells.

7. 7. The method of claim 5, wherein the percentage of viable counted cells is from about 10% to about 100%, or from about 68% to about 85%.

8. A plurality of the dissociated retinal cells are incubated in a 0.5% to 10% O 2 The method according to any one of claims 5 to 7, wherein the incubation is carried out at 37°C under 50°C.

9. 1. A method for culturing isolated primary human retinal cells to generate a population of non-immortal human retinal progenitor cells, the method comprising: (a) seeding a plurality of primary retinal cells produced by the method of any one of claims 1 to 8 into one or more coated culture flasks or plates containing culture medium at a first passage to produce a plurality of cultured retinal cells; (b) seeding a plurality of cultured retinal cells generated in said first passage into one or more coated culture flasks or plates containing a culture medium in a second passage; (c) seeding a plurality of cultured retinal cells generated at said second passage into one or more coated culture flasks or plates containing culture medium at a third passage; (d) cryopreserving a plurality of the cultured retinal cells; Including, The coated culture flask or flasks each have an area of ​​1 square centimeter (cm 2 ) approximately 0.5 x 10 4 1 cm from the cell 2 Approximately 5 x 10 6 Cells are seeded at a density of the seeding density of the first passage is greater than the seeding density of the second passage; and the seeding density of the second passage is greater than the seeding density of the third passage; Thereby generating said population of non-immortal human retinal progenitor cells.

10. 10. The method of claim 9, further comprising the step of seeding a plurality of cultured retinal cells generated by the immediately preceding passage into one or more coated culture flasks or plates containing culture medium in one or more additional passages.

11. 11. The method of claim 9 or 10, wherein the culture flask or plate is coated with xeno-free fibronectin, ornithine, polylysine, laminin, or a combination thereof.

12. The method of any one of claims 9 to 11, wherein the period between passaging is 2 to 8 days, 3 to 6 days, 4 to 5 days, or 3 to 4 days.

13. A plurality of the primary retinal cells or the cultured retinal cells are cultured in a culture medium containing 0.5 to 10% O 2 The method according to any one of claims 9 to 12, wherein the culture is incubated at 37°C under a temperature of 100°C.

14. The plurality of primary retinal cells are cultured at the first passage, (1) trypsin or TrypLE and ethylenediaminetetraacetic acid (EDTA), or (2) Trypsin or TrypLE, EDTA and DPBS The method according to any one of claims 9 to 13, wherein the cellulose is dissociated with a first enzyme solution comprising:

15. A plurality of the cultured retinal cells are cultured at the second passage, (1) trypsin or TrypLE and ethylenediaminetetraacetic acid (EDTA), or (2) Trypsin or TrypLE, EDTA and DPBS The method according to any one of claims 10 to 14, wherein the cellulose is dissociated with a second enzyme solution comprising:

16. 16. The method of any one of claims 14-15, wherein the plurality of primary retinal cells is dissociated at 37°C for about 5-20 minutes, about 6-10 minutes, or about 7-8 minutes.

17. wherein the plurality of cultured retinal cells is at the third or further passage; (1) trypsin or TrypLE and ethylenediaminetetraacetic acid (EDTA), or (2) Trypsin or TrypLE, EDTA and DPBS The method according to any one of claims 10 to 16, wherein the cleavage is carried out with a third enzyme solution comprising:

18. 18. The method of claim 17, wherein the plurality of cultured retinal cells, at least in the third or further passages, are dissociated at 37°C for about 5-10 minutes or about 5-7 minutes.

19. At the first passage, about 0.5 x 10 6 From about 3.0 × 10 6 cells / cm 2 , and about 0.1 x 10 6 to about 0.5 × 10 6 cells / cm 2 , and about 0.03 x 10 6 to about 0.2 × 10 6 cells / cm 2 , and about 10,000 to about 60,000 cells / cm for the fourth and further passages. 2 The method according to any one of claims 9 to 18, wherein the cells are seeded in a culture flask or plate at a density of

20. The cryopreservation of step (d) comprises: (i) enzymatically dissociating the cells using trypsin or TrypLE; (ii) stopping the dissociation with an excess of the culture medium or Advanced DMEM / F12; (iii) centrifuging the cells through a centrifugation at 10×g to 10,000×g for 1 to 30 minutes; (iv) resuspending the cells in culture medium and determining total cell number and viability; (v) adding cryopreservation medium to achieve a final dimethylsulfoxide (DMSO) concentration of 5-30%; (vi) aliquoting a plurality of cells into each cryovial; (vii) freezing each vial using a controlled rate freezer; and (viii) Drain each vial of cells into liquid N 2 Put in The method according to any one of claims 9 to 19, comprising:

21. The method of any one of claims 3 to 20, wherein the transport cell culture medium of claim 3, the culture medium supplemented with antibiotics of claim 5, the culture medium contained in the one or more coated cell culture flasks or plates of claim 5, the culture medium contained in the one or more coated culture flasks or plates of claim 5, the culture medium contained in the one or more coated culture flasks or plates of claim 9, the culture medium contained in the one or more coated culture flasks or plates of claim 9, the culture medium contained in the one or more coated culture flasks or plates of claim 9, the culture medium contained in the one or more coated culture flasks or plates of claim 10, the culture medium of claim 20, the culture medium of claim 20, the culture medium of claim 20, and / or the cryopreservation medium of claim 20, are serum-free.

Citation Information

Patent Citations

  • Isolation and transplantation of retinal stem cells

    JP2003521910A

  • Method for generating photoreceptors from human retinal progenitor cells using a polycaprolactone substrate

    JP2015505459A

  • Compositions and methods for treating retinal diseases

    JP2017035108A

  • Culture medium for proliferating mammary epithelial stem cells

    JP2017536827A

  • Three-dimensional culture method using biodegradable polymer and culture substrate enabling cell transplantation

    WO2016068266A1